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ABSTRACT 
Computation technology has dramatically changed the world around us; you can hardly find an area where 
cell phones have not saturated the market, yet there is a significant lack of breakthroughs in the 
development to integrate the computer with biological environments. This is largely the result of the 
incompatibility of the materials used in both environments; biological environments and experiments tend 
to need aqueous environments. To help aid in these development chemists, engineers, physicists and 
biologists have begun to develop microfluidics to help bridge this divide. Unfortunately, the microfluidic 
devices required large external support equipment to run the device. This thesis presents a series of several 
microfluidic methods that can help integrate engineering and biology by exploiting nanotechnology to help 
push the field of microfluidics back to its intended purpose, small integrated biological and electrical 
devices.  I demonstrate this goal by developing different methods and devices to (1) separate membrane 
bound proteins with the use of microfluidics, (2) use optical technology to make fiber optic cables into 
protein sensors, (3) generate new fluidic devices using semiconductor material to manipulate single cells, 
and (4) develop a new genetic microfluidic based diagnostic assay that works with current PCR 
methodology to provide faster and cheaper results. All of these methods and systems can be used as 
components to build a self-contained biomedical device.  
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Chapter 1 
Development of Microfluidic Devices with the Use of Nanotechnology to Aid in the 
Analysis of Biological Systems Including Membrane Protein Separation, Single Cell 
Analysis, and Genetic Markers 
Introduction 
Since the early 1990’s, medical devices and diagnostics (MDDs) have enjoyed 
success and development within certain medical niche applications, such as blood sugar 
monitors and heart rate monitors. Recent advances and innovations, however, have the 
potential to make medical device technology a ubiquitous technique that could be used by 
almost every field of science; by bringing the laboratory to the field with the advent of 
nanotechnology development and fully integrated devices. MDDs have the potential to 
integrate an entire laboratory onto a single chip system. The devices ensure the reduction 
of reagent volumes and reaction times, making them cost effective for any lab 
environment. Furthermore, the reduction of sample size by use of chip technology 
provides an excellent opportunity for science to turn “green” with the reduction of waste 
products. Potential applications for utilizing chip technology in MDDs include the testing 
of pharmaceuticals and biotechnology products for drug discovery and development, 
development of medical assays and portable testing devices, isolation, and separation of 
proteins to evaluate function/structure relationships, detecting nano- and pico-gram 
quantities of chemicals or biological agents that may be used for terrorist activities, and 
the rapid detection of disease states to address public health issues.1,3,4,6 The first 
generation of MDDs now entering the marketplace emphasize flexibility and usefulness 
in a variety of contexts, a trait that the industry deems crucial to the device’s commercial 
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success, such as Motorola Labs single-use portable self-contained full-scale automated 
DNA amplification and detection device (Figure 1.1).5 
 
Figure 1.1. Self-contained Microfluidic Device. This Microfluidic device was a one-time-
use only system developed by the Motorola Corporation for DNA amplification and 
detection. Unfortunately, it was a single-use only system. 
 
 One of the great appeals of MDDs is the interdisciplinary nature of the 
application. With the advent of microfluidics, optics, and microchip technology, 
numerous scientific methodologies and almost any technique has the potential for 
miniaturization. Another indication that MDDs have become a critical area of 
examination is the proliferation of journals focusing specifically on MDDs, as 
exemplified by the journal Lab on a Chip (Figure 1.2).  
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Figure 1.2. Lab on a Chip.25 An academic journal dedicated to advances in microfluidic 
research. 
 
Basic Principles   
Microfluidics refers to a set of technologies that control the flow of minute 
quantities of liquids, and on rare occurrences, gases produced in the device. The first 
MDDs manipulated solutions of less than 1 mL. Today, microfluidic laboratories are 
using fluidics that measure nano- and pico-liter amounts of sample.7 “Unlike 
microelectronics, in which the current emphasis is on reducing the size of transistors, 
microfluidics is focusing on making more complex systems of channels with more 
sophisticated fluid-handling capabilities,” as detailed by George Whitesides, of Harvard 
University.8 Although micro and macrofluidics systems require similar components, 
including pumps, valves, mixers, filters, and separators, the physics behind the two types 
of fluids are completely different. As the scale decreases from macro to microchannels, 
the flow of fluid begins to behave differently at the microscale. Surface tension, viscosity, 
and electrical charges can become dominant forces on the microfluidic flow, because the 
surface-to-volume ratio is much greater than for macroscale systems. In the microfluidic 
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system, fluid reacts differently than for larger fluid volumes; hence, microscale 
components require new fabrication methods. 
All of the current challenges in generating microfluidics relate to the ability to 
control the movement of the fluid inside the device. Traditional methods used for 
controlling fluid movement are not effective when scaled to the small volumes used in 
microfluidics; the physics behind the movement of fluid is different for very small 
volumes.13 For example, the forces (surface tension) exerted on very small volumes by 
the wall of the channel can restrict flow rates or cause particles to fall out of solution. In 
contrast, the surface forces exerted upon the movement of large volumes of fluid in a 
channel are negligible, because the surface to volume ratio is small. Thus, the critical 
element needed for this field to develop is a reliable mechanism to control the movement 
of the solution inside the device.11 It is one thing to simply inject liquid into a chip and 
generate a reaction, but having the ability to direct that fluid into a series of channels and 
divide it into numerous samples represents a level of sophistication that has yet to be 
perfected in microfluidic devices. 
 
History 
The microfluidic medical devices first developed in the early 1990s were initially 
fabricated in silicon and glass using etching techniques adapted from the 
photolithography industry, as shown in Figure 1.3.10,12 The generation of these devices 
was a time consuming process, often taking  
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Figure 1.3. Common Glass Microfluidic Device. Typical microfluidic devices  found in 
the commercial market.  
 
several days or even weeks to fabricate. The devices that were generated using this 
technique demonstrated excellent precision but were very expensive to produce, and were 
very inflexible, since they were all fabricated out of glass, which made widespread use 
impracticable. The current trend in microfludic chip development has moved toward the 
application of soft lithography fabrication methods, based on printing and molding of 
organic materials; poly(dimethylsiloxane) (PDMS) is the most widely used silicon-based 
organic polymer used to build microdevices, but there are many other polymers that can 
be used, each with its own unique chemical features. 
Microfluidics have shown great appeal for a number of applications, because they 
require only a small amount of volume and reagent (nanoliters) needed to perform tests, 
compared to microliter or milliliter requirements for existing standard laboratory test 
methods. Microscale reactions also occur at a much faster rate because of the unique 
physics of small fluid volumes; diffusion requires less time in a nanoliter volume than for 
larger microliter volumes. The current drive for microchip development is to make 
MDDs that prepare samples and perform automated routine assays. Such lab-on-chip 
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technologies hold the promise of turning a single chip into a multi-function laboratory, 
equipped to perform a series of applications (purification, protein labeling, reactions, 
separation, and detection) all within a volume of less than one microliter.  
 
Fabrication  
Photolithography fabrication of microfluidic chips begins with a horizontal 
channel design of a microfluidic pattern layout using a CAD program and with a high 
resolution printer, and that is printed on a transparency (Figure 1.4).14 Silicon wafers are 
obtained with the desired maximum microfluidic dimensions, using a wafer placed on a 
spincoater (Figure 1.5) to deposit a thin layer of the appropriate photosensitive polymer 
(photoresist). The photoresist becomes the horizontal distance of the microfluidic 
channel, so the rotation speed is determined by the thickness of the desired channel and 
the viscosity of the specific resist.9 Several types of photoresist are available, which can 
generate devices with a channel size range between 1-400 um. 
 
Figure 1.4. High Resolution Printer Transparency. Channel designs to generate masks for 
photolithorgraphy. 
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Figure 1.5. Spincoaters. Spincoaters are used to apply photoresist to silicon wafers. 
 
 Once the desired photoresist is applied, the wafer-photoresist mask is baked to 
remove the photoresist solvent layer. Once baked, the wafer is exposed to ultraviolet light 
through the overlaying transparency made using the CAD program. The mask-aligner 
(Figure 1.6) allows for the exact placement of the transparency onto the wafer. When 
generating a multilayer microfluidic, as seen in Figure 1.7, the mask-aligner allows the 
precise lineup of different transparencies to generate complex features. Instead of having 
a single layer microfluidic chip, layer upon layer of channels that interact with each other 
can be designed to fit any custom application (Figure 1.7). The ultraviolet light exposure 
is pictured in Figure 1.8. 
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Figure 1.6. Mask-aligner. An instrument used for multilayer fabrication and exposure of 
the microfluidic wafer to UV light. 
 
Figure 1.7. Multilayer Fabrication Diagram Expressing How Valves can be Generated in 
Microfluidic Devices .24 
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Figure 1.8. UV Exposure of Photoresist. Mask aligner exposure of photoresist-covered 
microscope slides with high-resolution transparences. 
Once the wafers are developed, the transferred microfluidic pattern is present on 
the silicon wafer. The areas of the photoresist that are exposed to ultraviolet light have 
different chemical properties than the unexposed photoresist. During the developing 
process, the unexposed photoresist dissolves faster than the exposed region, leaving the 
desired microfluidic pattern. The pattern is then used with a desired polymer to make the 
microfluidic device. For most devices, the polymer is poly(dimethylsiloxane) (PDMS).  
Once a microfluidic device is fabricated, the channels are exposed to the environment, 
allowing the chips to become plasma oxidized binding the polymer to the glass substrate.   
Several microfluidic laboratories have used these techniques for the construction 
of three-dimensional networks of channels and components.19 Figure 1.7 reveals how two 
overlapping channels can be used to create a microfluidic valve that provides a high level 
fluid flow control.17 Using a similar technique, microfluidics constructed with a 
multilayer system can control the movement of fluid to different segments of the device 
for controlled reactions.16 This method of fabrication has its advantages, especially when 
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using semiconducting material to generate microfluidic devices. The following chapters 
will question the idea of just using wafers as a mask for microfluidic device development.  
 
Ink-Jet to Biochips 
             Microfluidic technology started in the computer industry with ink-jet printing. 
Ink-jet printers use orifices of less than 100 µm in diameter to generate drops of ink unto 
the paper (Figure 1.9).  In this simple process, printers control a small amount of the 
fluid, making them the first MDD. This same ink-jet technology is now used in 
biotechnology to deliver reagents to microscopic arrays on the surface of biochips.15 
These biochips are used in many different scientific fields, especially in the 
pharmaceutical industry where arrays are used to determine drug reactivity.  
 
Figure 1.9. Microfluidic Droplets from an Ink-Jet Printer.26 
 
Just like the ink-jet printers, most microfluidic devices use electrokinetic and 
pressure methods to move small amounts of fluid around a microchip. The manipulation 
of fluid is the key principle for developing medical devices. Unfortunately, the techniques 
described above are useful only for certain microfluidic applications, particularly medical 
devices that only require straight channels; for many other applications, having a 
microfluidic device that has channel flexibility is essential.  
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In the late 1990s, Stephen Quake fabricated three-dimensional structures from 
multiple layers of soft elastomer by imprinting each layer and then binding them together 
to form the pumps, valves and channels integral to the microfluidic chip.24 This enabled a 
single microfluidic chip to serve many functions. With three-dimensional microfluidics, 
sample preparation, manipulation of live cells, perfusion of reagents, and analytic sample 
detection can be achieved on a single device, providing flexibility in fluid manipulation 
to generate small lab-on-chip systems. 
 
Polymers 
 MDDs are fabricated from polymers that are cured on a template created from the 
remaining photoresist. Of the readily available polymers, the most widely used is PDMS 
(Figure 1.10). PDMS is a silicon-based organic polymer that is extremely inexpensive.  
Once cured, the polymer (< 200 microns) is visibly clear, capable of providing a platform 
for fluorescence detection, as seen in Figure 1.11.16 The polymer is very versatile when 
applied in the liquid form and baked, and the polymer will take the shape of any design.  
However, the polymer cannot handle harsh solvents or high pressures and is only 
partially transparent to ultraviolet light (UV), where the thickness of the polymer 
determines the amount of UV transparency.  There are other polymers used to make 
MDDs. For example, sifel is a perfluoropolyether backbone with a terminal silicone 
cross-linking group that has the potential to take the place of PDMS.  It is stable to many 
organic solvents that degrade PDMS, but is expensive. In addition, it forms a cloudy 
material unlike PDMS, making detection through the polymer problematic. With all of 
the advantages that PDMS has in the field of microfluidic development, it is the best 
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material to use. The following chapters will address alternatives to PDMS that can still be 
optically transparent, yet have a greater reagent and pressure versatility not found in 
PDMS. Even though the cost is greater, the benefits of building fluidics inside 
semiconductor material enable cheaper medical devices. 
 
  
a) Ball model representation b) Name model representation  
Figure 1.10. PDMS Structure. Chemical composition of PDMS polymer. 
 
Figure 1.11. PDMS Microfluidic Device. Side view of a microfluidic device made from 
PDMS polymer. 
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Detection 
 There are several detection methods used with MDDs, including ultraviolet (UV) 
light, conductivity, magnetic binding, and fluorescence.18  Fluorescence detection is used 
extensively. Fluorescence occurs when a given wavelength of photons is directed to a 
molecule that triggers the emission of another photon with a longer wavelength. With this 
emitted light, the concentration of protein present can be quantified by knowing the 
extent of derivatization on a protein and how many green photons are being released. 
This detection method is highly effective for determining low concentrations of samples, 
yet fluorescence is much more of a versatitle tool than a simple detection mechanism, and 
it might be possible to get more information using fluorescence to gather information 
other than concentration. 
 
Conclusion 
 Over the next decade, the field of nanotechnolgy in conjuction with microfluidics 
will continue to evolve and advance, generating smaller, more complex MDDs. Instead 
of having samples shipped to diagnostic laboratories, samples will be processed in the 
field with little expertise. The US Defense Advanced Research Projects Agency 
(DARPA) envisions that microfluidics can solve the problem of inadequate medical care 
in the third world by reducing overall medical costs for detection and treatment of 
diseases, with the same high standards of detection that can only be found in modern 
medical laboratories.21 With skyrocketing medical costs, MDDs might also be the 
solution to help reduce overall medical expenditures. 
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Chapter 2 
A Microfluidic-Based Method for Recovering Enhanced Enzymatic Activity of 
Membrane Bound Proteins 
 
Introduction 
 
One common system for determining protein function is to understand their 
tertiary structure using x-ray crystallography to reveal the outside surface geometry of the 
protein, which can be used to determine binding sites. The use of x-ray crystallography 
has yielded the 3-D structure of nearly all soluble proteins, but this method is limited, in 
that it cannot be used to determine the tertiary structure of membrane proteins, since 
these membrane proteins are not soluble under physiological conditions and are 
imbedded in a non-soluble lipid bilayer. As a result, the 3-D structures of only a small 
number of membrane proteins are known.   
Membrane proteins represent important key regulators of material and 
information transfer between cells and their environment. They are the gatekeepers for 
the movement of material into and out of the cell. Membrane proteins also serve as 
structural elements of the cell itself, and between compartments comprising organ 
systems. Specific defects in membrane proteins are associated with many known diseases 
and as such, are the targets of many pharmacologically and toxicologically active 
substances to treat disease. Thus, an improved understanding of membrane proteins 
should provide stronger more selective drugs with fewer side effects. Understanding of 
the structure, function, and mechanisms of integral membrane proteins is difficult due to 
the limitations of successfully separating and purifying proteins from their encasing lipid 
environment. 
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 The isolation of membrane proteins, to study their physiological activity, is 
limited, since many of the current methods used for isolation denature the protein and 
change their 3-D conformational structure, which affects their function (binding 
capabilities, enzymatic activity, etc). When protein separation from the lipid environment 
occurs, the 3-D conformation of the native protein, needed for understanding the 
molecular machine, is typically not the same conformation of the protein in the natural 
environment; hence only a limited amount of information can be obtained.  A major 
hurdle to understanding the structure and function of membrane proteins is the 
reproducible procedure for isolating the membrane proteins in a mono-dispersed form 
that maintains the phospholipid-protein native structure and functionality.27 Furthermore, 
many of the membrane protein functions are not independent, but require other proteins 
for activity; they are just one part of a network of proteins that can span all regions of the 
cell. Thus, the isolation of just one protein may not represent the complete physiological 
function.   
Techniques are available to study the molecular structure and function of soluble 
proteins, but few techniques are available to study membrane proteins. One new method 
of isolating membrane proteins uses nanodiscs and allows for separation of protein with 
their membrane intact.28 In this method, a cell membrane preparation containing the 
target membrane protein is totally solubilized with detergent in the presence of a 
membrane scaffold protein (MSP). After removal of the detergent by dialysis or by Bio-
Beads, a soluble MSP-supported nanodisc is formed, with the target incorporated into the 
resulting phospholipid bilayer.29 Unfortunately, in the nanodisc-based technique, the 
amphiphilic detergent (such as 0.5 M cholic acid) that solubilizes the membrane protein 
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simultaneously separates the proteins from their native lipid bilayer, affecting their 
structural and functional features. 
  Through the use of microfludic technology, it is possible to isolate proteins from 
their membrane bi-layer without affecting the 3-D structure or functionality, by limiting 
the time that the detergent interacts with the membrane protein (see Figure 2.1). The 
precise control afforded by the lab-on-chip system, for the reaction between membrane 
proteins (sample) and a mixture of detergent and membrane scaffold protein (MSP) 
(reagent) to dissolve the lipid bi-layers into soluble nano fragments of transmembrane 
proteins, is influenced by regulating the flow rate, temperature controlling elements, and 
detergent quenching beads. 
 
Microfabrication of a microfluidic chip 
 The first microfluidic devices were fabricated at Caltech’s Nanofabrication 
Laboratory.  These devices were manufactured with a complex network of valves and 
control channels that made the device difficult to use. Subsequently, microfluidic chips 
were fabricated at Kavli Nanoscience Institute. These microfluidic chips were of a 
simpler design, using only a one-channel layer with no complex valve 
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Figure 2.1. Schematic Presentation of the Membrane Isolation Preparation Process. 
Membrane proteins are removed from the membrane with some lipid still attached to the 
protein. The cell membrane images (Figure 2.1) are from Wolf.31 
 
system. Each mold of the microfluidic device was fabricated from Dow Corning Sylgard 
184, a two-part cure silicone cast on photoresist, which generates a master mold.  The 
molds are made by spin-coating photoresist onto a silicon wafer, where the spin rate 
determines the horizontal distance of the microfluidic channel that is formed. A pattern 
with a high-resolution transparency mask (typically 3,386, 8,000, or 20,000 dpi) is placed 
on the silicon wafer with photoresist.  The transparency mask determines not only the 
pattern of the microfluidic device, but also the maximum longitudinal distance of the 
channel. As a result, the only variable that can be controlled once a transparency mask is 
made is the vertical distance or thickness of the microfluidic channel itself. After the 
channel is formed, the unexposed photoresist is removed using developer and the 
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resulting wafer is washed in an alcohol solution (preferably isopropyl alcohol) and then 
deionized water. The resulting wafer is dried under compressed nitrogen and baked for 90 
minutes in a 300°C oven.  After the wafer is cooled, Poly(dimethylsiloxane) (PDMS) is 
added onto the surface of the wafer and baked until the polymer is hardened to produce 
the microfluidic chip, as seen in Figure 2.2.  
 
 
 
 
Figure 2.2. Microfluidic Chip Preparation: a) Application of photo resist, b) UV exposure 
of the wafer, c) PDMS application. 
 
The resulting devices are cut from the mold and mounted onto thoroughly cleaned 
glass microscope slides. Mounting is accomplished by exposing both the glass and the 
microfluidic chip to plasma oxidation, and rendering their surfaces hydrophilic by 
creating silanol groups that interact with the glass surface. The completed microfluidic 
chip is presented in Figure 2.3. 
 
Membrane Isolation 
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 Rat membranes were custom isolated by the Burnham Institute (La Jolla, 
CA) according to the method of Meier et al.40 Specifically, rats were euthanized and their 
livers were rapidly removed and chilled on ice. Ten-gram portions of liver were cut into 
small pieces, washed three times in 80 mL of cold 1 mM NaHCO3 (pH 7.4), and 
homogenized in the same volume of 1 mM NaHCO3 with a loose (Type A) Dounce 
homogenizer (seven up-and-down strokes).  The homogenate was further diluted to 1800-
2000 mL with cold NaHCO3 and filtered twice through two layers of 60-grade 
cheesecloth.  The filtered solution was centrifuged at 1,500 x g for 15 minutes (GSA 
rotor, E.I. du Pont de Nemours & Co., Inc., Sorvall Instruments Div., Newtown, CT). The 
resulting “crude nuclear pellet,” was resuspended in 5.5 pellet volumes of 56% sucrose 
(wt/wt; density = 1.2623) and stirred for 15 minutes to disrupt membrane aggregates. The 
sample was dynamically loaded onto a 100 mL cushion of 56% (wt/wt) sucrose with a 
 
 
Figure 2.3. Microfluidic Design and Fabricated Device. a) Initial design of the 
microfluidic chip. b) Actual fabricated microfluidic chip.  
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variable-speed pump (Sorvall Instruments) into a zonal rotor (TZ28) and overlaid first 
with 400 mL of 44% sucrose (wt/wt; density = 1.1972), followed by 200 mL of 36.5% 
sucrose (wt/wt; density = 1.1587).  The rotor was completely filled to its total volume 
capacity (1,350 mL) using 0.25 M sucrose.  During the entire loading procedure, the rotor 
is running at 3,000 rpm.  The completed discontinuous sucrose gradient system is 
centrifuged at 20,000 rpm for 120 minutes.  After a slow deceleration to a complete stop, 
70 15 mL fractions were collected from the bottom of the rotor.  Each fraction was 
analyzed for density, turbidity (absorbance at 700 nm), and marker enzymatic (alkaline 
phosphatase) activity.  Fractions containing the bulk of the plasma membrane fragments 
(e.g., fraction 54-64 out of 70) were combined and diluted with 250 mMol NaHCO3 to 
1,000 mL.  The suspension was centrifuged in a rotary centrifuge at 7,500 x g for 15 
minutes and the pellet was gently resuspended (by vortex mixing) in 250 mL of NaHCO3 
pH 6.4. The resuspended material, representing the liver plasma membrane, was 
resedimented at 2,700 x g for 15 minutes. A total quantity of 5 g of concentrated rat liver 
membrane in 250 mMol NaHCO3 solution was received from the contract laboratory.  
Cell membranes from S. oneidensis strain MR-1 were obtained from cultures 
grown in Luria-Bertani (LB) medium at 25°C. For aerobic growth (high oxygen), 20 mL 
of LB broth was inoculated with 1 mL of overnight culture and placed in a 250 mL flask 
which was incubated on a rotary shaker at 200 rpm. The cells were harvested at the 
exponential phase (OD600 = 1). For low oxygen growth, the speed of the rotary shaker 
was reduced to minimize oxygen uptake. The membrane sample from S. oneidensis was 
obtained from Dr. Vladimir Kery, Molecular Biosciences, Pacific Northwest National 
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Laboratory, according to our material transfer agreement.  The membranes of S. 
oneidensis were prepared according to the method of Giometti et al53 and separated from 
the soluble components by high-speed centrifugation. 
 
Sample preparation procedure 
 
A. Membrane Sample Preparation.   
Frozen cells were thawed and immediately mixed with two volumes of lysis 
buffer containing 50 mM glucose, 10 mM EDTA, 25 mM Tris-HCl, pH 8.0, and 4 
mg/mL of lysozyme in the presence of protease inhibitors (complete mini protease 
inhibitor cocktail; Roche Diagnostics, Indianapolis, IN). Lysozyme was added to the lysis 
buffer immediately before use. The solution was sonicated then shaken at 4°C for 12 
hours.  The resulting lysate was centrifuged for 40 minutes at 12,000g in a refrigerated 
Eppendorf centrifuge to remove unbroken cells.  The supernatant was collected and 
centrifuged at 160,000g for 30 minutes in a Beckman (Beckman-Coulter, Fullerton, CA) 
TL100 tabletop ultracentrifuge, followed by an additional 10 minutes of centrifugation at 
435,000g for further purification. The additional ultracentrifugation step increases the 
purity of the membrane sample since active lysate may still be present, degrading the 
desired proteins.  The final supernatant was collected as the soluble cytosolic fraction, 
and the pellet was suspended in lysis buffer containing 0.5% w/v CHAPS detergent (Bio-
Rad, Hercules, CA).  The resuspended pellet was transferred into a chilled Dounce 
homogenizer and evenly dispersed with 10 slow strokes of the pestle.  The dispersed 
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pellet was collected as the crude membrane preparation.  The crude membrane fractions 
were stored at -80°C for further analysis. 
 
B. Preparation of the Nano-Disc Samples:  Rat Liver Membrane.   
 The concentrated rat liver membrane sample, prepared as described above, was 
diluted 100 fold with 0.05 mM Tris-HCl buffer pH 8.0.  In accordance with the procedure 
for self-assembly of Nanodisks,29 the rat liver membrane was detergent-solubilized with 
0.5 M cholic acid and mixed with human apoprotein A1 (University of California, San 
Diego Biology Department) and detergent in the approximate ratio of 1:100:200 
(apoprotein/membrane/detergent).  The reconstituted samples, which include 
approximately 100 nmol of scaffold protein, 10 mmol of membrane, and 20 mmol of 
cholate, were preincubated for 1.5 hours at 4°C. The detergent was removed by 
incubating with Bio-Beads® SM-2 Adsorbent (approximately 0.4 g Bio-Beads®/1 mL of 
reconstitution mixture) for 1.5 hours at 4°C. 
 
C. Preparation of the Nano-Disc Samples:  Shewanella oneidensis Membrane.  
 Nano-Discs containing Shewanella oneidensis membrane were prepared as 
follows. Concentrated Shewanella oneidensis membrane was diluted 100 fold with 0.05 
mM Tris-HCl buffer pH of 8.0. The diluted sample was mixed with 0.5 M cholic acid and 
human apoprotein A1 in the approximate ratio of 1:100:200 
(apoprotein/membrane/detergent) and incubated at 38°C for 1, 2, 3, 4, 5, and 6 hour time 
intervals. At the conclusion of each time period, the detergent was removed by incubating 
with SM-2 adsorbent beads for 2 hours at room temperature. All samples were filtered 
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through a 30 nm filter, and the concentration/absorbance of the solubilized cytochromes 
were measured in an ELISA reader at 410 nm.  The concentration of the released 
transmembrane cytochromes gradually increased with an increase of the incubation time 
of the sample, reaching its plateau after 5 hours of incubation. 
 
D. Preparation of the Membrane Nanofragments: Rat Liver Membrane.  
Rat liver membrane was mixed with apoprotein A1 and 0.5 M cholic acid 
(detergent) in the approximate ratio of 1:100:200 (apoprotein/sample/detergent) and 
heated to 38°C. The heated sample was injected through separate ports of the 
microfluidic chip into the mixing chamber and stirred using magnetic nanobeads. Once 
the sample was mixed, the liquid was moved through the macrofluidic compartment, 
filled with SM-2 adsorbent beads (BioRad Laboratories, Hercules, CA) (approximately 
0.4 g of BioBeads/1 mL), cooled to 4°C, and sent into the outflow port of the chip. A 
micofluidic membrane separation was performed using incrementally increasing flow 
rates of 1 mL/minute, 5 mL/minute, 10 mL/minute, 20 mL/minute, and 50 mL/minute.  
The processed samples were collected in centrifuge tubes at the outflow port and 
analyzed. 
 
E. Preparation of the Membrane Nanofragments:  Shewanella oneidensis 
Membrane 
The Shewanella oneidensis membrane sample was incubated in 0.5 M sodium 
cholate at 38°C for 2 hours prior to initiating the separation procedure. After the 
conclusion of the heat-treatment step, the treated sample was mixed with apoprotein A1 
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and 1.5 M sodium cholate and again heated to 38°C. The mixture was injected into the 
mixing chamber of the microfluidic chip, and moved to the macrofluidic separation 
compartment as described previously. The membrane separation process was performed 
using low flow rates of 0.1, 0.5, 0.8., 1.0, and 2.0 mL/minute. The processed samples 
were collected in centrifuge tubes at the outflow port and analyzed.   
 
Apparatus 
The microfluidic chip apparatus that was used for the membrane protein isolation 
studies is described in Figure 2.4. The design of the chip uses two solution ports, one for 
membrane samples and the other for detergent. There is a mixing chamber for the two 
solutions to interact and start the reaction between the detergent and membrane solutions. 
Two parallel warming channels are used to increase the reaction temperature to 38°C.  
Conversely, two parallel cooling channels are used to reduce the temperature of the 
reaction to 4°C. The final process releases the solution to the quenching bead chamber. 
 
Experiment 
 A. Fluid mixing 
The initial concept to use nano-magnetic beads in the micofluidic mixing chamber was to 
stimulate the mixing of the two fluids, while preventing laminar flow. Experiments with 
unfunctionalized magnetic nanobeads (Dynal Biotech) were designed to introduce 
vortices within the fluid flow region and, therefore, enhance mixing. However, the 
direction of the nanobead movement, using an external magnet (Figure 2.5), was not able 
to overcome the energy provided by the flow rate. The nanobeads would follow the 
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solution flow aligned with the magnetic field, but they did not greatly disturb the laminar 
flow. Figure 2.6 shows that the magnetic beads are experiencing laminar flow even 
though there is a rare earth magnet trying to collect the beads into the chamber.   
 
 
 
Figure 2.4. Conceptual Function of the Microfluidic Device. Description of how the 
microfluidic chip controls fluid movement and reaction temperature to perform the 
membrane separation reaction. 
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(a) (b) (c) 
 
Figure 2.5. Magnetic Beads in the Reaction Chamber: a) A magnified view of a 
microfluidic channel with magnetic beads; (b and c) In the presence of a rare-earth 
magnet at two orientations.   
 
 
 
Figure 2.6. Laminar Flow out of the Reaction Chamber. Nanobeads in the reaction 
chamber demonstrating how the magnetic beads move by laminar flow out of the reaction 
chamber. 
 
The final microfluidic device design naturally produced a laminar flow of the 
sample in a reaction chamber, sandwiched between two identical reagent flows (Figure 
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2.7), and it was this system that was used as a solution mixing control indicator. By 
controlling the relative ratio of sample and reagents, and their total flow rates, the 
reaction time can be precisely determined, which is governed by diffusion of 
sample/reagent and the length of the microfluidic channel. The fluid layer channels are 
100 mm wide and approximately 25 mm high, which can hold a maximum of 11 nL of 
solution. Mixing was achieved by a laminar-flow mixing system, and the mixing time 
was determined by the diffusion time between the sample and reagent flows. Given that 
the sample and reagents react as long as they are in contact with each other, by 
controlling the distance (channel length) they travel and rate at which they travel (flow 
rate) the diffusion limited reaction time can be accurately controlled.  
 
B. Analytical procedures 
The microfluidic protein isolation system was evaluated using both eukaryotic 
and prokaryotic microbial membranes. The extracted nanofragments were filtered with a 
30 nm polycarbonate filter, to select all fragments smaller than 30 nm and the 
concentration/absorbance of the solubilized cytochromes was measured in ELISA reader 
at 410 nm. The concentration of the released transmembrane cytochromes gradually 
increase, with the increase of the incubation time of the sample, reaching its plateau at 5 
hours of the incubation. As a control, the activity of the unfiltered starting sample was 
compared to that of the filtered sample. 
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Figure 2.7. Laminar Flow Diagrams. a) Membrane flow rate exceeds the flow of the 
detergent channel. b) Detergent flow rate exceeds the rate of the membrane channel. 
 
Alkaline phosphatase activity was measured in ELISA microplates using 150 mL 
of each of eight samples. The microfluidic chip samples were collected at flow rates of 1, 
5, 10, 20, and 50 mL/minutes. A Nano-Disc sample and unprocessed, filtered, and 
unprocessed unfiltered samples were included in the assay.  A reaction 
mixture/incubation medium (150 mL) consisting of 0.5% p-nitrophenylphosphate and 1 
mM MgCl2 in 0.05 mM Tris-HCl buffer of pH 8.0 was added to the triplicate samples. 
 Control samples for the enzymatic reaction consisted of buffer only and twice 
diluted incubation medium without sample, as a reaction mixture control. The 
microplates were incubated at 37°C in sealed Ziploc bags to prevent evaporation. The 
enzymatic reaction was stopped after 15 minutes by adding 100 mL of a 1 M potassium 
phosphate solution. An incubation time of 15 minutes was determined from prior studies 
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as optimal for enzyme activity. The optical density of the p-nitrophenol product released 
was measured by an ELISA reader at 410 nm. 
In addition to an alkaline phosphatase assay, the activity of peroxidase was 
measured in ELISA microplates using the same samples, controls, and assay methods as 
described above. The optical density of the peroxidase products was measured in an 
ELISA reader at 450 nm. 
 
Results 
Since laminar flow was used to mix the membrane with the detergent solution, as 
the flow rate increased the amount of time needed to fill the microfluidic chip decreased 
and lowered solutions interacting with one-another for membrane separation. The data 
presented in Figure 2.8 demonstrates the relationship between flow rate and interaction 
time to limit protein degradation, as the flow rate increases the amount of time needed to 
fill the 10 nL device is reduced.  
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Figure 2.8. Reaction Time Vs Flow Rate. The reaction region is estimated to contain 
approximately 10 nL of material. 
 
The current best membrane separating system available for extracting proteins 
from prokaryotic sell membranes is the Nano-Disc system, which only generates an 
ELISA optical activity reading of around 0.15 (Figure 2.9). In contrast, when the 
microfluidic chip system is used on the same membrane source by controlling the flow 
rates, the separation yield is almost twice the optical activity density. The data also 
reveals that at every flow rate measurement, the microfluidic system is equal to or better  
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ELISA Reading vs. Flow Rate for Shewanella oneidensis 
 
 
Figure 2.9. Activity of the Peroxidase Enzyme. 15 membrane samples of the Shewanella 
oneidensis: Microfluidic chip samples at 0. 5; 1.0; 2.; 5.0; 10.0 and 20.0 mL/minute flow 
rate obtained from two separate chips, Nano-Disk sample (all filtered through 30 nm 
membrane filter), unprocessed filtered, and unprocessed unfiltered sample measured in 
ELISA microplates at 450 nm. 
 
than the current technology. The data also demonstrates that the system is not 
microfluidic chip dependent, since multiple reproducible results were generated in three 
separate experiments, revealing that these devices can be mass-produced with consistent 
results. 
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ELISA Reading vs. Flow rate for Fat Liver Cell.  
 
Figure 2.10. Activity of Alkaline Phosphatase. Sample of rate liver cells are run at 1 
mL/minute, 5 mL/minute, 10 mL/minute, 20 mL/minute, and 50 mL/minute flow rates in 
the microfluidic chip; Nano-Disc sample filtered through 30 nm pore filter (blue) or 
unfiltered (red), unprocessed, filtered and unprocessed unfiltered,  
sample measured in ELISA microplates by means of an ELISA reader. 
 
From the data presented in Figure 2.10, all experimental flow rates consistently 
showed equal or greater activity than the conventional Nano-Disc technique, with the 
microfluidic chip method yielding peak flow rates that contain two times the activity of 
the conventional method. This suggests that with the same sample size, the microfluidic 
system is able to generate almost twice the amount of separated active protein. As with 
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the prokaryotic cell membrane, the eukaryotic rat liver membrane proteins can be isolated 
using the microfluidic chip by controlling the solution mixing to ensure active membrane 
separation.  
 
Conclusion 
 Membrane bound proteins are the most difficult type of proteins to separate. 
There are only a handful of membrane bound proteins that have been isolated. Proteins 
that have been isolated typically have a denatured structure since the membrane is out of 
its native environment. Membrane proteins have both hydrophobic and hydrophilic 
regions, when imbedded into the cell membrane. Membrane bound proteins can be 
isolated from both eukaryotic and prokaryotic cell types using a microfluidic platform, 
with retention of activity that is far greater than using traditional separation techniques. 
With the precise control over the protein and detergent solution which microfluidics 
provides, proteins are clipped out of the membrane in small lipid disks, which now act 
like soluble proteins and can be studied by traditional methods. The active density of the 
ELISA test revealed that the amount of isolated protein is up to twice the concentration of 
that obtained from traditional methods. This technique furthers our understanding of how 
proteins function in a membrane system, because we can get key insights about their 
structure from their interaction with isolation media chemicals. Unfortunately, the ability 
of separating membrane bound proteins without denaturing is only one part of the 
problem in researching membrane bound proteins. The other key issue is that many 
membrane bound proteins require other proteins for their proper function. By simply 
separating one protein and studying its structure and some of its function without the 
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other proteins, there will still be unanswered questions. For future research, when a 
membrane protein is isolated it should also be examined with other cellular proteins to 
see if there are protein-protein interactions.  
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Chapter 3 
A Microfluidic Approach to Generate a Biomarker Monitoring Device 
 
 
Introduction 
It is well established that early detection of disease or rapid treatment of an injury 
will enhance an individual’s survival rate or minimize long-term injury. For a number of 
years, researchers have attempted to identify biological indicators that signal the onset of 
a disease or injury. These biological indicators have become known as body-borne 
biomarkers. These biomarkers provide vital information about a person’s health status 
and physiological effects of medications.54 Advances in proteomics have led to the 
discovery of a number of human biomarkers associated with diseases, post therapeutic 
reactions, and physiological conditions that signal developing cancers. Biomarkers 
provide an opportunity for the early detection of previously untreatable or low survival 
rate maladies, such as organ system failures. 
Rapid detection and identification of biomarkers, using body fluid samples, will 
not only aid early diagnosis and treatment of several diseases and adverse physical 
conditions, but have the potential to extend the average human lifespan by providing 
critical physiological data about the body before major damage can occur. Among the 
various types of biomarker detection technologies available today, a few are portable and 
do not require an expert to perform the diagnostic tests. These biomarkers are based 
primarily on four principles: electrochemical sensing,55 mechanical (piezoelectric) 
sensing,56 electrical impedance sensing,57 and optical sensing.58 The first three methods 
are known to be susceptible to environmental conditions (temperature, humidity, etc.), 
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and therefore produce a high percentage of false positives under ambient conditions. The 
fourth method can be classified into three main categories: fluorescence sensors, 
ellipsometric and interferometric sensors, and surface-plasmon-resonance-based sensors 
(SPRs).59 Fluorescence sensors require labeling of sample biomarkers for sensitive 
optical detection and are therefore time consuming to produce and require expert users. 
Fluorescence labeling also has the problem of needing a dark environment for reading the 
sample. In addition, the shelf life of each fluorescence label, if not stored properly, is 
only a few minuets to a couple of hours due to a high probability of photo bleaching. 
Ellipsometric and SPR sensors use several discrete optical components such as polarizers 
and analyzers, making them expensive and very sensitive to vibrational instability. Since 
these components need to be perfectly aligned to provide an optimal signal, any field 
applications where the device experiences excessive vibrations will produce poor results. 
Interferometric methods have limited throughput because of their complexity and lengthy 
signal processing times. Therefore, currently available point-of-care devices for the 
detection and measurement of biomarker concentrations, using this detection method are 
not appropriate for field applications requiring high throughput, field ruggedness, and 
ease of use by nonmedical personnel. Thus, given the limitations of each of these 
detection mechanisms, a new diagnostic system needs to be generated to not only 
withstand the harsh conditions provided in non-laboratory field applications, but to also 
have the sensitivity and throughput needed to detect biomakers. 
Biomarker monitoring device (BMD) performance is based upon optical loss 
characteristics during light propagation through an optical waveguide, with a surrounding 
medium that changes the refractive index through the specific surface binding of 
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biomarker proteins. As the density increases, the amount of light able to reach the 
detector increases.  A BMD incorporates a self-referencing mechanism to effectively 
eliminate false readings induced by changes in the light source and/or in ambient 
conditions. The BMD system requires a very small volume of reagent (<100 uL) and very 
little sample preparation, making it ideally suited for field applications and laboratory 
experiments. In addition, non-experts design the BMD for use, since the only requirement 
is injecting the sample into the correct inlet and running washing solutions between tests. 
A prototype BMD demonstration system was prepared using a custom-designed 
multimode optical waveguide sensor, consisting of four channels (two detection and two 
reference channels) such that test samples and controls are run simultaneously to ensure 
accuracy. The optical setup of the BMD system was designed to operate at a wavelength 
of 1550 nm, which is a common wavelength for protein detection. Most of the 
components of the BMD system were commercial off-the-shelf components. Two 
biomarker proteins (human lipocalin-2 [NGAL] and interleukin-18 [IL-18]), which are 
directly related to Delayed Craft Function (DCF) following kidney transplantation,60 
were detected with high specificity (>99%) from samples in a physiological buffer 
(phosphate buffered saline) and in spiked porcine blood at room temperature. The results 
showed that the BMD provided a unique bio-monitoring platform that was capable of 
detecting biomarker proteins with high specificity and sensitivity, without the need for 
labeling or the use of expensive reagents that might require expert preparation. 
 
  
38 
BMD construction and function 
The BMD sensor was fabricated by fusion splicing an 18.85cm-long termination 
fiber (Fitel OFS, Hampton, NJ) between two standard Single Mode Fibers (SMF-28, 
Corning Inc.). Since the termination fiber does not have any cladding, the aqueous buffer, 
which can be any fluid from phosphate buffered solution to whole human blood, 
functions as the cladding for the light guided into the sensor region (Figure 3.1). From the 
figure the sensor region is the center multimode fiber section where no cladding is 
present and light can escape from that region. As a result of this configuration, as the 
concentration of proteins that are bound to the fiber increases, correspondingly greater 
light intensity is able to reach the detector, generating a signal proportional to the amount 
of bound protein. The sensitivity of the BMD was evaluated using the design shown in 
Figure 3.2a. Sensitivity was measured by monitoring changes in the refractive index of 
the surrounding buffer medium when light at 1550 nm wavelength from a high-power (10 
mW) superluminescent laser diode (DenseLight, Inc., Singapore) was split and sent 
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Figure 3.1. Multimode Fiber Interferometer for the BMD Sensor. The configuration 
consists of two single-mode silica fiber sections (8 um core diameter, 125 mm cladding) 
at the ends, and a multimode fiber section (125 um core diameter) in the middle with no 
cladding. 
 
through the sensing and reference legs of the sensor, and the transmitted light signals 
were detected at detectors D1 and D2 (Thorlabs, Inc., Newton, NJ). To determine the 
refractive index sensitivity of the BMD sensor, signals at the detectors were measured 
simultaneously using liquids of different refractive indices. As the concentration of 
material increases in the liquids there are more opportunities for light to reflect off that 
molecule and back into the fiber at the detector (Cargille Laboratories, Cedar Grove, NJ). 
Each liquid can also absorb the laser light ejected from the sensory region, and this too 
can be an accurate measurement, because the signal to the detector would be reduced 
compared to the control. The measurements were conducted by surrounding the sensing 
channel with media of varying refractive indices (1.3 to 1.4) while the reference channel 
was maintained in phosphate buffered saline. The measured results are shown in Figure 
3.2b. 
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The slope of the measured response (Figure 3.2b) is 15.44dB/unit refractive 
index. If the optical detector system is capable of measuring an optical loss with 0.01 dB 
accuracy, the sensitivity of the BMD sensor to refractive index changes will be  
6.5 ´ 10-4dB. This refractive index sensitivity compares well with other types of optical 
fiber sensors, including fiber grating sensors (Figure 3.3). While the refractive index 
sensitivity of the prototype sensor was in the order of 10-4, it can be improved by at least 
an order of magnitude by optimizing the length of the multimode waveguide sensor, 
making it comparable to other devices on the market. With the fiber fusing and splicing 
process that was used to fabricate the BMD prototype sensor, it was difficult to control 
the length of the multimode waveguide, as the variation in the slicing process is more 
than one hundred micrometers, resulting in a small amount of inconsistency from one 
sensor to another. 
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(a) (b) 
 
Figure 3.2. Design of a BMD Sensor. (a) BMD design for the sensor head, light source, 
detector, data acquisition (DAQ) system, and microfluidic device. (b) Measured optical 
loss using the BMD sensor as a function of the refractive index of the surrounding 
medium (cladding). 
 
BMD applications 
A. Immobilization of Antibody on Sensor Surface 
 
Immobilization of antibodies on a glass surface using Poly-L-lysine (PLL) is reported in 
the literature62,63,64,65. In the BMD sensor, poly-L-lysine (Sigma P8920) was used to 
immobilize avidin proteins (Sigma A9275) on the fiber surface as shown in Figure 3.4. 
Fluorescein-labeled biotin in phosphate buffered saline (PBS, Sigma, B9431) 
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(a) 
 
(b) 
      
Figure 3.3 a and b. Optical Field in the Multimode Waveguide. Optical loss as a function 
of refractive index of the cladding for different multimode waveguide lengths. 
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Figure. 3.4 Fiber Preparation. Immobilization of avidin on an optical fiber surface, 
followed by BSA as a blocking reagent. 
 
was used as the target molecule. The immobilization protocol used for this process is as 
follows: (1) the surface of the fiber is cleaned with a 3:1 (v/v) methanol:chloroform 
mixture, (2) the fiber is washed with with pure (HPLC grade) methanol, (3) the fiber is 
rinsed in deionized water and dried in a nitrogen stream at room temperature, (4) the 
cleaned fiber surface is immersed in a solution containing poly-L-lysine in deionized 
water (0.01% w/v) for 30 minutes, (5) the Poly-L-lysine coated fibers are arranged in a 
vertical position to ensure that a uniform monolayer of PLL is formed on the surface, and 
(6) the coated fiber is dried in a temperature controlled oven at 45°C for 30 minutes. In 
order to get stable immobilized proteins by covalent bonding, the PLL coated fiber 
surface is treated with 1-ethyl-3-(3-(dimethylamino) propyl) carbodiimide (EDC) for 10 
minutes. EDC surface activated fiber is immersed in a freshly prepared solution of avidin 
(50 mg/mL in PBS buffer, pH 7.2) and stored overnight at 4°C. After removing the fiber 
from the avidin solution, the fiber is rinsed in PBS buffer and the PLL surface is treated 
with a bovine serum albumin (BSA) solution (1 mg/mL in PBS buffer) for 15 minutes at 
room temperature to block any available non-avidin binding sites on the PLL coating. 
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Excess BSA is removed by rinsing the PLL coated fiber in PBS buffer (pH 7.2). The fiber 
sensor surface is ready to capture biotinylated target molecules. 
The efficiency of the immobilization method was evaluated by binding five 
different concentrations (1, 10, 25, 50, and 100 pg/mL) of fluorescin-labeled biotin 
(excitation wavelength 488 nm, emission wavelength 514 nm) to five separate avidin 
coated PLL fibers. Each of the avidin-immobilized optical fiber waveguides was 
incubated in a separate fluorescin-labeled biotin sample for approximately 5 minutes. The 
sensor surface was washed using PBS buffer and the fluorescence images were visualized 
and recorded using a fluorescence microscope equipped with a CCD camera. The binding 
efficiency results are shown in Figure 3.5. The intensity of observed fluorescence 
indicates a uniform avidin/biotin binding on the waveguide surface, and the amount of 
binding is proportional to the biotin concentration in the sample solution. No measurable 
fluorescence was observed for fiber coated with the 1 pg/mL biotin sample. 
 
B. Fabrication of the Microfluidic Chip 
Master templates for the BMD MDD were fabricated in a silicon substrate using standard 
UV lithography with SU8 photoresist, as shown in Figure 6a.  Features, such as micro-  
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100 pg/mL 50 pg/mL 25 pg/mL 10 pg/mL 
 
Figure 3.5. Fluorescent Images of Fluorescin-Labeled Biotin Coated Fibers. Fluorescence 
images were taken from a CCD camera attached to a microscope.  Different 
concentrations of fluorescent labeled biotin were bound to avidin molecules immobilized 
on the optical fiber surface. The fluorescent label was excited by 488 nm light, and the 
emission wavelength was 514 nm. 
 
channels with cross-sections of 300 um x 400 um, were fabricated using multistep 
photolithography for the BMD prototype. The process flow diagram (steps a-c) and the 
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resulting devices are shown in Figure 3.6b. Poly(dimethylsiloxane) (PDMS) MDDs were 
fabricated by a simple molding and lift-off process. 
 
 
 
 
Figure. 3.6a. A Microfluidic Template. Master template fabricated by SU8 lithography on 
a silicon substrate. 
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(a) (b) (c) 
 
Figure 3.6b. PDMS Mold Fabrication. (a) The fabrication process flow, showing the 
molding steps to obtain a PDMS MDD; (b) a fabricated microfluidic device, and (c) 
microfluidic device with fluidic interconnects. 
 
Access to the fluidic channels was produced by mechanically drilling 300 um 
holes in the molded PDMS. Platinum ferrules were inserted into these drilled holes and a 
syringe was attached to the inlet port ferrule via a flexible tube for assaying sample 
buffers. Laying the multimode waveguides on a cleaned glass plate and sealing them with 
the PDMS MDD, as shown in Figure 3.6(c), completed sensor assembly. 
 
 C. Investigation of Avidin/Biotin Binding on the Sensor Surface 
Experiments were conducted with a prototype sensor to detect unlabeled biotin 
using the same immobilization method described above. The experimental setup is 
identical to the one shown in Figure 3.3, with the exception that the MDD had common 
inlet and outlet points for the sample buffer flow. Avidin was immobilized on the sensing 
arm of the sensor before the fiber waveguides were assembled within the microfluidic 
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channels. Transmitted light signals from the sensing and reference fiber legs were 
recorded. Initially, both channels of the sensor were filled with PBS buffer to collect the 
background signal. Four different sample solutions, each with different amounts of biotin 
in 50, 100 and 500 pg, and 1 ng in 100 ul volumes, were prepared for the experiment. 
First, a sample with the lowest concentration was pumped into the microfluidic channels 
and the detector signals were recorded immediately after the pumping had stopped. 
During the pumping of samples, the detector signal showed several spikes due to the 
mechanical disturbances induced by the flow pressure on the sensor elements. To 
reconstitute the sensor surface after each experiment, the sensor waveguides were flushed 
with freshly prepared 0.1 M glycine (pH 2.0) in PBS buffer for 2-5 minutes, followed by 
three flushes with PBS buffer (pH 7.2).  The test results are shown in Figure 3.7. 
The results show a clear difference in the detected signal level for the different 
concentrations of biotin in the sample buffer. However, the prototype sensor did not show 
a linear response with the concentration of the target molecules below 200 pg/mL. 
Variation in waveguide sensor length during the sensor fabrication process is believed to 
have contributed to this non-linearity. The large standard deviations in the sensor signal 
can be attributed to the loss of activity of the sensor surface during the repeated 
regenerative processes, as observed in Figure 3.8. 
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Figure 3.7. Optical Loss of Biotin. Experimental results from the BMD prototype sensor 
when different concentrations of biotin solutions were used in the detection channel. 
Each test point represents the mean and standard deviation of three test results. 
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Figure 3.8. Successive Regeneration of Biotin on a Avidin Coated Fiber Optic Cable. 
Avidin coated fibers were treated with labeled biotin then washed with pH 2.0 glycine. 
 
The fluorescent intensity, as detailed in Figure 3.8, is high during first and second 
applications. Since there is only one fluorescent marker on each biotin molecule this 
suggest that a high concentration of biotin attached to the avidin coated fiber, but after 
every successive wash application (a pH 2.0 glycine wash for 5 minutes) to clean the 
fiber surface from bound biotin, it becomes clear, especially after the third wash, that the 
levels of fluorescent intensity have decreased and specific segments of the fiber are much 
lower in intensity than other regions. By the fifth application the overall fluorescent 
intensity is dramatically lower than the intensity of the initial application. By the sixth 
application the amount of florescent label present is nearly negligible when compared to 
the first three applications of biotin. 
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Biomarker detection results 
Experiments were performed to evaluate the capability of the BMD to detect two 
biomarkers separately, as well as simultaneously. The experimental setup, shown in 
Figure 3.9, was used for evaluating the BMD to resolve biomarker specificity. The 
biomarkers, human lipocalin-2 (NGAL, MW 25kDa) and interleukin-18 (IL-18, MW 
44kDa), and their biotinylated antibodies were purchased from R&D Systems, Inc. 
(Minneapolis, MN). The experimental set up consisted of four channels, two detection 
channels (AB1 and AB2) and two reference channels (R1 and R2).  Each channel had a 
separate optical detector. Light from the superluminescent light emitting diode (SLED) 
was split into four different optical fiber channels using a 1´4 waveguide splitter and sent 
to the detectors via the BMD sensor channels. Waveguide sensor surfaces were 
immobilized with avidin as described previously. After treatment with a solution 
containing 3% BSA protein, sensor waveguide AB1 was immersed inside a sample buffer 
containing 10 ng/mL of biotinylated anti-lipocalin antibody, while sensor waveguide 
AB2 was immersed inside a sample buffer containing 10 ng/mL of biotinylated anti-
interleukin antibody. The reference sensor waveguides, R1 and R2, were kept in 
phosphate buffered saline (pH 7.2) during this process. All waveguides (detection and 
reference waveguides) were laid on a clean glass plate for 25 minutes and a PDMS 
microfluidic chip was aligned and sealed on top of the fiber waveguides. The 
microfluidic chip had one common entry and exit point for injecting fluid samples in and 
out of the channels. 
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Three different sample solutions were prepared from the two biomarkers as 
follows: 
Sample 1.  36 pmol NGAL-2 in Tris-HCl buffer (pH = 8.0). 
Sample 2.  0.22 nanomol IL-18 in Tris-HCl buffer (pH = 8.0). 
Sample 3.  Mixture of Sample 1 and Sample 2 at 1:1 (v/v). 
 
Four different tests, as described below, were designed to demonstrate the 
specificity of the BMD to resolve and identify each biomarker. 
Test 1:  No biomarker sample is injected into the microfluidic channels. 
Test 2:  100 mL of Sample 1 is injected into the microfluidic channels. 
Test 3:  100 mL of Sample 2 is injected into the microfluidic channels. 
Test 4:  100 mL of Sample 3 is injected into the microfluidic channels. 
 
During Test 1, all the microfluidic channels contained Tris-HCl buffer (pH 8.0).  Each 
subsequent test (Test 2 through Test 4) was performed using 100 uL of sample injected 
into the microfluidic channels using a glass syringe. The sensor system was cleaned after 
each test using 0.1 M glycine (pH 2.0) followed by rinsing with 0.1 M PBS (pH 7.2). 
Each sample was carefully injected to minimize mechanical disturbances inside the 
microfluidic channels. The system was left undisturbed for 2 minutes before the SLED 
light source was turned on, and the data from the photoreceiver array were continuously 
recorded for 10 minutes during each test.  The test results are shown in Figure 3.10. 
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(a)                                                                                                               
        
(b)           
 
 
Figure 3.9. Biomarker Monitoring Device Prototype. (a) Schematic of the BMD setup for 
simultaneously detecting two biomarkers: AB1 = detection channel 1; AB2 = detection 
channel 2; R1 = reference channel 1; R2 = reference channel 2, D1..D4 = optical 
detectors, and (b) the experimental setup. 
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(a) (b) 
  
(c) (d) 
 
Figure 3.10. BMD Sensory Data. Experimental results for all microfluidic channels in the 
BMD when filled with (a) PBS buffer (pH 8.0), showing no response in any channel; (b) 
Sample 1, showing a response only in channel AB1; (c) Sample 2, showing a response 
only in channel AB2; and (d) Sample 3, showing a response in both channels.  
 
The experimental results show that the BMD sensor channels immobilized with 
different antibodies respond to only the specific biomarker of interest. No cross-
sensitivity between the two tested biomarkers was noticed during repeated experiments. It 
was observed that the sensitivity of the sensor response continuously decreased with the 
number of repeated tests due to a loss of activity on the sensor surface. However, the 
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sensitivity was sufficiently high for the BMD to detect the presence of the biomarkers 
after four regeneration process steps. It should be noted that the concentration of NGAL 
and IL-18 biomarkers in Test 4 was 50% lower than the concentrations used in Test 2 and 
Test 3.  These results demonstrate that the BMD is capable of specifically resolving the 
tested biomarkers. 
A series of experiments were also performed to investigate the sensor response 
when the biomarker proteins are contained within a whole blood matrix. Porcine blood at 
room temperature was mixed with the same biomarkers as identified previously. 
However, the biomarker sample solutions were prepared at a concentration of 100 ng/mL 
in PBS buffer (pH 7.2). The solutions were then mixed with the porcine blood in a 1:5 
ratio, resulting in a final concentration of 20 ng/mL. The test method was identical to that 
described previously with the exception that porcine blood was substituted for Tris 
Buffer. First, the microfluidic channels were filled with porcine blood to record the 
baseline reading. The sample solution containing both biomarkers in spiked porcine 
blood was injected into the sensor system and the signal was recorded (Figure 3.11). 
The data demonstrate that a difference in signal level is clearly distinguishable 
when there is whole blood in the channel and when the biomarkers are present in the 
blood sample. It should be noted that the rate of change in the sensor signal for the IL-18 
biomarker is smaller than that of the NGAL biomarker, which is consistent with the 
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Figure 3.11. BMD Sensory Data of Biomarkers Spiked into Whole Porcine Blood.   
 
previous tests performed with biomarkers present in PBS buffer. Depending upon the 
binding rate and the affinity of the antibodies for the biomarker, some biomarker proteins 
may require more than ten minutes of incubation time to induce a change in the refractive 
index so that the optical signal can be distinguished from its baseline value. 
 
Conclusion 
The feasibility of a new optical sensor, based upon optical loss in single mode to 
multimode light guiding properties of waveguides, to simultaneously detect at least two 
biomarkers at picomolar concentrations with nearly 100% specificity was demonstrated. 
The BMD prototype detected two different biomarkers, human lipocalin-2 and 
recombinant human interleukin-18, at nanogram/mL concentrations using less than 100 
mL of sample. This sample volume represents a significant decrease in sample volume 
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from any commercially available instrument on the market today. The test data also 
demonstrated that the sensor element of the BMD (uncladded fiber optic cable covered in 
a specific protein) could be reused by a simple regenerative process that removes all of 
the biological matter for replacement with another protein. Although it is not clear if the 
reduction of signal is the result of degrading the avidin protein on the fiber, or the 
stripping of the poly-l-lycine from the fiber surface, for either case the optical fiber can 
be re-prepared with more poly-l-lycine solution with added desired protein to create a 
new active biosensor. The BMD prototype test system was designed to simultaneously 
evaluate two biomarkers. However, many more biomarkers can be simultaneously 
evaluated because the only limiting factor is the number of fiber optic cables that can be 
linked together and thus the power to send concentrations of light through the system. 
This new sensor system represents the promise of a smaller, faster, and more easily 
handled hand-held biomarker monitoring device for point-of-care applications than any 
current existing sensor systems. The BMD allows for fast, on-the-spot data collection, 
eliminating the time required to transport either a sample or a person to the test site to 
analyze the data. 
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Chapter 4 
Generation of Microchannels in Silicon on Insulator Wafers 
Introduction 
Microfluidic devices for all their convenience have not had the vast impact on 
science and creating portable laboratories as many have hoped; this is the unfortunate 
result of needing large equipment to run these small devices. The reaction chambers and 
reagents required are small, but many fluidic devices require valves, pumps, and 
detection equipment that turn these tiny devices into a large complex network of 
instruments. The Axel Scherer lab has strived to turn microfluidics back into the intended 
purpose; small integrated devices in which all of the detection and controls are self-
contained in the device. The first step in the integration process is to use materials that 
can both handle the biological or chemical samples being analyzed and can also be used 
for mechanical and electrical components needed to accomplish these tasks66, 70. We can 
limit our search for new materials by looking for some key properties: a material should 
be relatively chemically inert and optically transparent, and be able to handle pressure 
and ideally have some electrical properties; one such material is silicon on insulator 
(SOI) wafers66,70,71.  
SOI wafers are composed of a three layer material stack of the following: an 
active layer of prime quality silicon (DEVICE LAYER) over a buried layer (BOX) of 
electrically insulating silicon dioxide over a bulk silicon support wafer (HANDLE), as 
shown in Figure 4.1. In electrical engineering SOI are replacing bulk silicon wafers  
(approximately 0.75 mm thick) with wafers that have three layers: a thin surface layer of 
silicon (from a few hundred Angstrom to several microns thick) where the transistors are 
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formed, an underlying layer of insulating material, and a support or "handle" silicon 
wafer. The insulating layer, usually made of silicon dioxide and referred to as the "buried 
oxide" or "BOX", is usually a few thousand Angstroms thick, but can be several microns 
thick. When transistors are built within the thin top silicon layer, they switch signals 
faster, run a lower voltages, and are much less vulnerable to signal noise from 
background cosmic ray particles. Since on an SOI wafer each transistor is isolated from 
its neighbor by a complete layer of silicon dioxide, they are immune to "latch-up" 
problems and can be spaced closer together than transistors built on bulk silicon wafers. 
Building circuits on SOI allows for more compact chip designs, resulting in smaller IC 
devices (with higher production yield) and more chips per wafer (increasing fab 
productivity).  
Since SOIs are already used in the fabrication of transistors, is it possible to use 
this material for other purposes. By exploiting the buried oxide layer of SOI and the fact 
that we can selectively etch different materials, is it possible to generate a channel inside 
an SOI without significant damage to the top layer of silicon, and if this can be 
accomplished, what properties does this new type of device have that can be beneficial to 
generating an integrated fluidic device?  
Device Fabrication 
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FIG. 4.1A     FIG. 4.1B 
 
 
 
 
 
 
 
 
 
FIG. 4.1C     FIG. 4.1D 
Figure 4.1A, B, C and D. Outline of the SOI channel fabrication process. Schematic 
representation of the process that develops fluidic channels inside the oxide layer of 
silicon on insulator wafers. 
A. Wafer Thinning 
1. Chemical Mechanical polishing 
A wafer was sent out to Aptek Industries, Inc. for their chemical 
mechanical polishing procedure. 
2. KOH ething 
1. Place chip in beaker of NH4OH:H2O2:DI water (1:1:40) for 3minutes 
at room temperature (1a). Blow dry. 
 2. Rinse with HCL:H2O2:DI water (1:1:40) for 3minutes at room 
temperature.  
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3. Blow dry. 
4. Spin apply PSB primer at 2000 rpm with 500rpm/s ramp for 60 
seconds.  
5. Soft bake at 110oC for 1 minute . 
6. Hard bake at 220oC for 5 minutes. 
7. Spin apply ProTEK PSB coating at 2000 rpm with 500rpm/s ramp for 
60 seconds.   
8. Soft bake at 110oC for 2 minutes.  
9. Expose using 365nm (i-line or Suss Channel 1) for 40 seconds.   
10. Post-exposure bake at 110oC for 2minutes.  
11. Develop chip in Ethyl Lactate for 10 seconds.  
12. Blow Dry. 
13. Repeat steps 11-12 until fully developed.  
14. Hard Bake at 200oC for 3 minutes. 
15. Perform undercut in KOH or TMAH. (at 2.5hrs of 75oC KOH that I 
get an undercut of ~120microns. This is significantly increased at KOH 
temperatures above 80oC.)  
16. Rinse with IPA or water. 
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17. Remove PSB protective coating with Piranha. 
B. Mask development 
1. Clean wafer with IPA and water. 
2. Spin desired photoresist. 
3. Expose wafer with e-beam or UV light in desired pattern. 
4. Develop resist. 
C. Pseudo Bosch etch 
1. SF6 etch gas while simultaneously passicated with C4F8. 
D. Channel Etching 
1. Submerge wafer in HF bath. 
2. After desired etch time excessively wash wafer in DI water. 
3. Bake wafer for 2 hours at 150oC. 
E. Channel Sealing 
1. Grow a layer of oxide which will seal the etch hole, or 
2. Deposit metal on the wafer, which will fill the etch hole, or 
3. Spin coat a polymer layer and heat cure to fill holes. 
Test Device 
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Figure 4.2 Procedural Outline for SOI fabrication. Outline of the pattern order 
for the generation of SOI fluidics. 
Developing a new fluidic device 
 
Figure 4.3 First Attempts at Generating Channels Inside an SOI Device. Proof of concept 
test to determine if it is even possible to generate channels in a SOI device. 
 There is no guarantee that an idea will be feasible even when the science behind 
the idea is sound. In Figure 4.3, which is a simple light microscope image though the top 
layer silicon, to observe the developed channels reveals one of the benefits of using 
SOI’s, silicon is optically transparent. I attempted to generate simple pattern channels 
inside SOI devices of straight lines and bends, using e-beam lithography; the holes were 
Defining cavities in the 
insulating (oxide) layer  
Depositing a material, 
polymer on top of the cavities, 
or grow an oxide layer 
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500nm sample holes and 50nm bulk channel holes. The procedure was not optimized, but 
even without optimization it was possible to generate channels. The SOI wafer use had a 
top silicon thickness of 400nM and an oxide layer of 2um. 
 
Figure 4.4 SEM Image of HF Generated Channel and Oxide Between the Two Channels. 
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Figure 4.5 SEM Image of Channels Inside SOI Device.  SEM image of first generation 
SOI channels displaying channel etch inconsistency. 
 By closely examining the device in Figure 4.5 using an SEM we can observe that 
the HF etch process is not uniform along the channel; as expected the channel is 
significantly larger in the proximity of the larger holes in the top layer silicon, yet the 
channel around the smaller holes should be more uniform, but this is not the case. Where 
the larger holes generate a channel around 20uM in diameter at its narrowest the smaller 
holes only generate a channel that is 10um. To understand why this occurs, the 
magnification needs to be increased to have a closer to look at the holes that have been 
etched in the silicon. There is a relationship between the hole size and channel diameter, 
where the larger the hole size will generate a larger channel in the SOI wafer, yet this 
relationship is not clearly observed in Figure 4.4. 
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Figure 4.6 Closer SEM of First Generation SOI Channels. Increased magnification of  
SOI  etch holes. 
 To understand why the oxides etch is not uniform over the channel, a closer 
examination of the HF access holes is needed. The etch process for the SOI channels is 
diffusion mediated, and the HF needs to move into the SOI to interact with the oxide and 
generate water and SiF2, which needs to diffuse out of the newly formed channel. As we 
can conclude, diffusion is the process that allows for the etch chemical to reach its target, 
and the larger the access hole, the higher the diffusion rate. As displayed in Figure 4.6, 
we can see different access hole and from the image we can observe that not only are the 
smaller holes not completely uniform, but many appear to be obstructed. From the initial 
trial we can see that it is possible to generate channels in the oxide layer of SOI, but the 
system needs optimization. 
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Figure 4.7 System for SOI Parameter Optimization. Auto Cad design and e-beam test 
pattern to optimize parameter. 
 There are three major variables that need to be optimized to help generate better 
channels from the initial trial; one being hole size, the second being hole spacing and the 
third is the e-beam dosage to generate the holes. Once the hole parameters are optimized 
channel etch times would also need its own optimization later in the process. To test these 
parameters simultaneously I generated a patterns (seen in figure 4.7) to test for the ideal 
hole size and spacing array to test different e-beam dosage. The hole size ranged from 
25nM to 1uM and hole spacing from 100nM to 5uM, as seen in Figure 4.8.  
A"
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Figure 4.8 E-beam Writing of Optimization Patters. One single copy of an array to test e-
beam dosage and hole geometry for channel development. 
 The e-beam dosage helps to define the features in the photoactive polymer applied 
to the surface of the wafer; if the dose is too low the feature edges will be misshapen or 
will not develop properly, overexposure of the photo polymer will lead to significant 
morphological damage and misshapen features. As a result there is a balance between 
getting the correct dosage to define the features without overexposing and damaging the 
resist. There is also a inverse correlation between feature size and e-beam dosage. The 
larger features require a lower dosage and smaller features require a higher dosage. The 
dosage testing is displayed in Figure 4.9, where the small feature dosage is written first, 
followed by the large feature dosage, where a small feature is any feature below 50nM 
and the large feature is greater than 50nM.  
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Figure 4.9. Test Array for E-Bean Optimization. 
 After several trials it was determined that for large features (100nM to 1uM) an e-
beam dosage of 300-400 uC/cm2 is needed, for middle range features (50nM to 100nM) 
an e-beam dosage around 1000 uC/cm2 is needed, and anything smaller than 50nM needs 
dosages greater than 1300 uC/cm2. Figure 4.10 shows the importance of e-beam dosage 
to generate uniform holes. The dosage used was 1000 uC/cm2 and we can see the larger 
holes on the right have distorted edges, which results in overexposure, we can also 
observe the holes blend together when the hole spacing is too small. We get the opposite 
effect when the features are too small on the left side of the image. The holes are barely 
visible, which was to due to underexposing the polymer; these features can be lost 
without proper development, resulting in the loss of the pattern in the next step of the 
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process. The features in the bottom center of the pattern are well defined, uniform, and 
clear, which will generate a clean etch.  
 
Figure 4.10. 1000 uC/cm2 Dose at 300 Magnification. At 1000 uC/cm2 the feature 
definition displayed for different hole sizes and hole distances. 
 After parameters were tested it was discovered that hole spacing was less critical 
in allowing for an ideal etch when compared to hole size, yet the distance between the 
hole will define the exact length and width of the channel being generated. Using a hole 
feature size of 100nm in diameter several devices were submerged in buffered HF. 
Several devices at different HF exposure times were measured in the SEM, as seen in 
Figure 4.11. As mentioned before the HF etch process is diffusion mediated, and 
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eventually fresh HF will not be able to diffuse into the channel and reach the oxide layer. 
Figure 4.11 shows that after 30 minutes the HF etched about 2uM of oxide, in an hour 
5uM, and after 1 hour and 20 minutes about 7uM of oxide had been etched. With longer 
time exposures the oxide is significantly reduced; there appears to be no more significant 
oxide etch for the given hole diameter after the hour and 20 minutes of etching. If the 
device is left in the buffered HF for a longer time you would have significant loss of 
oxide layer along the edges of the device, and as a result you would need to protect that 
oxide before processing a long etch. The etch time is optimized to the 100nM diameter 
feature size, and if a larger or smaller hole is used to generate a channel another 
optimization test would need to be performed. Using this information the hole feature 
spacing can be designed for a channel to the exact length and width desired. 
Etching through the oxide layer occurs in spheres, as seen in Figure 4.12, 
centering on the access channel through the silicon layer. As the sphere grows it meets 
the bottom silicon surface, which has a significantly slower etch rate than the oxide layer, 
essentially stopping channel growth in that direction. Etching continues in the other 
directions of the oxide layer until it meets up with other etch spheres and a complete 
channel is formed, as seen in Figure 4.13.  
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HF 
Figure 4.11 HF Etch Time and Distance Etched in SOI Wafer. SEM images of buffered 
HF exposed SOI wafers after pseudo bosch etch to remove silicon allowing for HF 
diffusion in oxide layer. 
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Figure 4.12.  Diffusion Etch Inside and SOI Device. SEM image of buffered HF oxide 
etch of a single access channel in a SOI device 
 
Figure 4.13. Optimized SOI channel. SEM Image of a Channel Formed with an SOI 
Wafer. 
 Now that the optimization parameters were determined, a complete clean channel 
inside the SOI wafer was created, as seen in Figure 4.13. From the image we can observe 
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that the channel walls are almost 7uM away from the access hole with 2uM distance 
between the access holes. Examining the surface of the SOI device is helpful to optically 
distinguish between the etched oxide and the remaining oxide; however, to see how the 
HF etch affected the walls of the channel inside the device, I used the Nova 600, which is 
a dual-beam focused ion FEI, to cut an access port to provide a mechanism to image deep 
inside the channel (Figure 4.14).  
 
Figure 4.14. Internal Channel Access Port. SEM image after the top layer of silicon was 
removed. 
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Figure 4.15 SEM Image of the Inside an SOI Channel. SEM image of the channel 
developed by the removal of oxide of an SOI wafer. 
 With closer examination of the channel (Figure 4.15) we can observe a difference 
between the top and bottom length of the channel. As mentioned before, the channel is 
created by diffusion of HF inside the access hole and when etching the oxide in a 
spherical fashion the upper wall will be longer than the lower wall. We can also see the 
spherical etch with the oxide that remains on the wall, since the access holes are spaced 
(Figure 4.15) by 1uM small regions of oxide protruding inside the channel. The dimples 
on the bottom surface of the device were generated when the top layer of silicon was 
etched away to image inside the channel. Similar to traditional microfluidics, where the 
channel height is determined by the photopolymer used to generate the channel, SOI 
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fluidic height is determined by the oxide layer.  As displayed in figure 4.16 we can 
observe that the channel height is 1.75uM. 
 
Figure 4.16 SEM Image of SOI Channel Height. SOI channel height is limited to the 
height of the initial oxide layer of the SOI wafer. 
  If we increase the magnification, as seen in Figure 4.17, we can observe that the 
top layer silicon is 364nM thick. The bowing of the top layer silicon is the result of how 
the SOI is manufactured. Either taking two wafers or growing oxide on both generally 
fabricates SOIs and then wafer bonding the oxide layers together, or only growing oxide 
on one wafer and then wafer bonding with an oxide-free wafer. Both processes will cause 
stress, and as the oxide is removed the stress causes the observed bowing in the channel. 
This stress ends up not being a problem for biological experiments, since the pressure and 
temperature used is not sufficient to break the top silicon layer. 
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Figure 4.17 Bowing of Silicon Layer. As oxide is removed internal stress in top silicon 
layer is revealed. 
Conclusion 
 SOIs have the potential to improve the current properties of microfluidic devices 
and focus on flexible polymers and reintroduce material that was discounted, biased on 
material properties. By building fluidics into the materials used to develop computers 
new levels of miniaturization can be achieved that were not possible with current fluidic 
technology. The development of the microfluidic valve by Steve Quake help further 
miniaturize fluidics that still often require significant external equipment to run or 
detection of the fluidic devices. SOI have the potential to bridge the gap between the 
current fluidic technology and the future fluidic devices that have the biological and 
electrical components made from the same material. The current polymers can still be 
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used for valuing and contribute to fluidic movement, yet other materials are superior for 
actual biological or chemical experiments. Development of a new fluidic device has its 
own unique challenges, first in trying to generate a working system, but also in 
optimizing the parameters associated with fabrication. I have proved that it is possible to 
form channels inside semiconductor material by exploiting the unique properties of the 
material itself by selectively etching the oxide layer and leaving the silicon layer 
relatively undamaged. With this design we have the potential to build the electrical 
components for movement and detection directly on the fluidic system without the need 
for external equipment. SOIs also have the advantages of having unique surfaces to 
preform selecting binding and specific regions, where the channel walls are silicon oxide 
and the top and bottom surface is silicon; this feature can be useful for future 
development of SOI channel experiments, specifically focusing on the ability to separate 
biological samples electrically. 
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Chapter 5 
Eletrofluidics 
Introduction 
The ability to move fluid in a microfluidic device was accomplished with the use 
of pumps or systems of valves that function as a pump; unfortunately, as expressed 
earlier, this requires external equipment to control this movement, which turns a micro 
device into a macro system. Using the developed SOI microchannels from the previous 
chapter is it possible to use the properties of the semiconductor material to move objects 
inside the channel without the aid of external equipment or valves. 
I have developed, integrated and tested a new class of on-chip controls over 
fluidic components that can be easily integrated within the microfluidic chip designs. 
These new devices hold tremendous potential for very real clinical applications that will 
directly affect current clinical treatment of many disorders; for the purpose of this study, 
the system focused on cancer detection. The fluidic device used micro-electrodes to 
manipulate individual cells and nanoliter reagents within micro-channels for single-cell 
molecular analysis. As a result of this capability for single cell detection, this device will 
change how we treat cancer patients, by determining molecular profiles of individual 
circulating tumor cells (CTCs) or, as revealed in a later chapter, how the device can be 
used to determine the genetic variation of cells. Currently there are no tests available that 
can predict which breast cancer patients would benefit from trastuzumab beyond disease 
progression, in part because clinical decisions are based on the HER2 status of the 
primary tumor biopsy, and not on that of the metastatic tumor. Because a tumor is a 
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dynamic disease and various mutations can arise during treatment, determining the 
current HER2 status of the metastatic tumors is critical for treatment decision. However, 
multiple tumor biopsies during treatment are too invasive for most patients, and new 
metastatic tumors are too small and too many for biopsy. To address this problem, I have 
developed devices that can do real-time cell sorting, which would allow a determination 
of the HER2 tumor status from a regular blood draw by molecular analysis of single 
CTCs.  
Recent work has shown that the number of CTCs in a patients blood is a novel 
predictor of clinical outcome.78-80 CTCs were identified in cancer patients with a 
variety of metastatic cancers, with a median yield of 50 cells/ml and purity ranging from 
1 to 80%.81,82 Enormous effort is being expended to develop methods for non-invasive 
tumor biopsy and CTCs assessment.  However, most systems are specialized on CTC 
enumeration, and lack the capacity of single-CTC molecular characterization. Our 
proposed system stands out from others with molecular characterization of single-CTC in 
addition to CTC enumeration.  
Microfluidic devices for clinical use in CTC enumeration and CTC molecular 
characterization should be robust and trouble-free. Because of the rare number of CTCs 
that can be obtained form a patient blood sample (typically less than a few hundred cells), 
the capacity for molecular characterization  of single cells is critical to extract useful 
molecular information from CTCs.  I built an electrical control design to replace the 
cumbersome peripheral support devices of traditional microfluidic devices for a trouble-
free device. The proposed device has lithographically defining electrical valves and 
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pumps with the functionality of controlling picoliter volumes of reagents and isolating 
rare CTCs through dielectric differences within microfluidic channels. Key components 
for the system will be fabricated in a metal layer directly on SOI fluidic channels, and 
samples will actually flow through electrophoretically. CTCs will be detected and 
isolated with frequency-dependent conductivity signals. The whole system has no 
moving mechanical components, yet before any cancer cells can be tested I will test the 
system with beads and similar sized cells to observe if it is possible to electrically 
manipulate a cell at a low voltage. 
Copper electrode cell concentrator 
 To fabricate the copper electrode a fabrication mask was made in Autocad; the 
design was sent to CAD Art Services to generate an optical mask. The mask was then 
placed on top of photoresist coated copper sheets and exposed to UV light. The sheet was 
then developed in hydrochloric acid, washed in water, and backed in an oven at 80oC 
overnight. The devices, seen in Figure 5.1, were then individually cut out of the sheet and 
used for testing. Testing was performed by linking the copper devices with a frequency 
oscillator and manipulating the frequency from 10Khz to 150kHz. 
 To initially test the idea of electrically manipulating cells I patterned an electrode 
in a copper sheet (figure 5.1). The system was designed to concentrate cells in a signal 
point of the center of the device using only one electrode. In Figure 5.3, we observe a 
close-up image of the copper pattern from this device, made using copper etch and UV 
light with an optical mask. The quality of the electrodes is not ideal. The electrode edges 
are jagged, which can change the overall frequency in that given area, but for a proof of 
concept, the device will work, although the device will have to be modified with further 
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experiments to generate better quality electrodes. Fluoresce labeled beads were diluted in 
a PBS solution spiked with calcium to make a 0.1 molar calcium PBS solution, although 
the PBS solution has ions for the movement of the bead, and calcium was used to add to 
the ion concentration. 
 The design was to use low voltage but variable frequency to move the beads, and 
since the test device will only use one electrode, the distance between the coppers will 
decrease as it gets closer to the center of the device (Figure 5.3). The voltage used was 
0.2 volts and a frequency of 50kHz, and since the copper electrodes are not u 
niform it is not possible to determine the exact frequency at a given level of the device. 
Before the device is powered the labeled beads are distributed around the device.  Once 
power is applied the beads quickly move between the electrodes, and as time progresses 
the beads start to concentrate towards the center (Figure 5.2). Since there is no system of 
electrodes the beads remain between the electrodes. After successful demonstration that 
the proof of concept works by manipulating beads, a redesign of the device was 
necessary to enable the movement of cells, having two electrodes is not sufficient  to 
move beads or cells and an array of electrodes is needed to move beads or cells. 
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Figure 5.1 Copper Electrodes. Copper electrodes on a fabrication sheet after exposure to 
UV light and hydrochloric acid etch. 
 
Initial distribution of beads 
 
Right after power turned on 
 
After several minuets of 
power on 
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Figure 5.2. Copper Electrode Test System. Individual copper devices were attached to a 
frequency generator and tested to observe the movement of labeled beads. The top image 
is with the device not powered, the middle image is power first applied, and the lower 
image is with power applied for 5 minutes and frequency range applied. 
 
Figure 5.3. Closer Image of Copper Device. With increased magnification we can 
observe that using UV optical mask lithography does not generate crisp electrodes. 
Electrodes made of chrome on glass 
Once the proof of concept was established with the copper electrodes determining 
the proper spacing of the electrodes themselves, new spacing requirements were needed 
to allow for optimum cellular movement. Using commercially available glass slides with 
chromium and photoresist already deposited, I used the Heidelberg Instruments DWL-66 
and later the EBPG laser to write the electrode designs with variable line spacing, as seen 
in Figure 5.4. The chrome masks were developed in M1039 developer (Microchem).  
From the image in Figure 5.4, unlike the copper electrodes, the chromium electrodes are 
more uniform. Although both processes involve photolithography, the copper electrodes 
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involve generating a mask followed by the exposure of the photoresist coated copper with 
UV light and etched with hydrochloric acid.  In contrast, the chromium electrodes are 
directly written with an e-beam system, allowing for greater resolution, and are 
developed and etched with chromium etch, which is a mixture of nitric and acetic acid. 
As with the initial problem when using only one electrode, when trying to move 
beads in the copper system, the chromium system must have multiple electrodes as well 
in order to create an oscillatory activation of electrodes, allowing the cell to move 
between active electrodes. This means that when designing the electrodes, no single 
active electrode should be active next to itself (Figure 5.4, right image). After several 
runs it was observed that there is a coloration between frequency and electrode spacing, 
and the greater the distance between the electrodes the higher the frequency that is 
needed to move the beads, with the optimum range between the electrodes of 100um or 
less. 
Using this information a new chromium mask (Figure 5.5) was designed where 
the electrode spacing was 100um between the same electrode, and either 40um or 60um 
between different electrodes. This design should allow for the cell to migrate to the center 
of each electrode when powered, and with the electrodes oscillating on and off the cells 
should move between the electrodes. Limited spacing between electrode pads was needed 
to ensure that the correct electrode is active at a given time (Figure 5.6).  
In attempt to replicate the conditions found with an SOI water glass microscope 
cover slides were used. Initially the glass sides were washed in a 50-50 mixture of 
chloroform and methanol, and rinsed with water. To prevent a solution of beads from 
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covering the glass slide completely, the slide was also coated with a thin layer of PDMS 
with a hole of bare glass left open for the experiment (Figure 5.7), to observe if beads 
will still migrate between the electrodes with the glass slide between the solution and the 
electrodes (Figure 5.7B).  As illustrated in the figure the labeled bead are migrating 
between the electrodes. With closer examination of the device, (Figure 5.8), we can in 
fact see beads migrating between the electrodes of the device with a glass coverslip 
covering the electrodes. The slightly darker bands are the electrodes and the lighter bands 
in the image are the spaces between the electrodes. 
  
A B 
Figure 5.4 A and B. Chromium Electrodes Patterned with Direct-Write Laser System 
Heidelberg Instruments DWL-66. 
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Figure 5.5 Chromium Etched Electrodes. Chromium electrodes spaced 100um, 60um, 
and 40um apart from each other.   
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Figure 5.6. Close-up Image of Chromium Etched Electrodes. Chromium electrodes with 
access pads to allow for attachment to function generator; crisp features are the direct 
result of e-beam lithography.  
  
A B 
Figure 5.7. Two Different Views of PDMS Covered Glass Slides. A PDMS covered glass 
slide with a sample port was fabricated and placed over chromium electrodes. 
 
Figure 5.8. Close-up Image of Glass Slide Cove Port. When frequency is applied we can 
observe the congregation of beads between the electrodes of the device. 
 Once the parameters were determined I started to fabricate the channels on SOI 
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devices with chromium electrodes. The cost of the SOI is significantly greater than that 
of simple glass, and hence the need for optimization was performed when compared to 
other devices. After successful device development I tested to see if beads could flow 
through the developed SOI channel (figure 5.9). To perform movement, the test device 
would either need a lower concentration of cells or wider channels. 
 
Figure 5.9. Beading Flowing Through an SOI Channel.  
Electrofluidic channels inside SOI devices 
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A B 
Figure 5.10. SOI Wafer Sorting Device 
 
A new system was fabricated out of SOI wafers where channels were developed 
with the technology presented in Chapter 4 and chromium electrodes; the device was then 
attached to a function generator for testing (Figure 5.10).  A single bead size was used to 
test if the new system still functions as in previous tests. In Figure 5.11 we can observe 
consistent test results as before, and when a function is applied to the electrodes the beads 
congregant between the electrodes. All the samples that were tested used simple single  
sized beads; to test to see if the system can actually preform the intended function, a 
complex sample of different size beads was used (Figure 5.12). 
 
Figure 5.11. Beads Congregating Between Electrodes. 
When testing the complex mixture, the sample was injected into the SOI device 
and then left to settle for an hour, as this should prevent any additional Brownian motion 
or added energy from the injection of the sample. The movement of the complex sample 
  
91 
can be seen in figure 5.11, and if we focus on the relative concentration of bead sized 
close to the injection site where the concentration of larger beads appears consistent, it 
appears to be uniform distributed (Figure 5.11 A), yet if we examine the beads farther 
down from the injection site the distribution of smaller beads is reduced (figure 5.11 B). 
The proposed mechanism is ion movement. As the frequency modulated in the device, 
ions either congregate towards or away from the electrode, and as this happens the ions 
push the cells like ships in the wind, and since larger cells have more surface area than 
smaller ones these cells move faster. This can be explained with a dielectrophoresis force 
equation (Figure 5.13), where r is the radius of a cell ε are permittivity and dielectric 
constants and Erms are the frequency and voltage applied, respectively. 
  
A. Close to the sample injection site B. Down stream of the sample injection site 
Figure 5.12. Complex Sample of Different Size Labeled Beads. 
 
Figure 5.13 Dieletrophoresis Force Equation. 
 The device works with beads, but the intent is to run human cells into the system 
to see if  larger cells can separate from smaller cells. Just as in the previous experiment I 
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injected the sample in the system and let it settle to prevent any false data from injection 
movement. After applying a 100kHz field at 0.2 volts I was able to observer movement 
of larger cells over smaller ones, as seen in Figure 5.14. It is difficult to display cell 
movement without a video; however, I was able to find a single small cell and a large cell 
where you can see that the larger cell moves at a faster rate than the smaller one. 
  
Figure 5.14. Separation of Cells by Size. Two cells with different size flow in a 100 um 
SOI channel by dielectrophores force generated with 0.2 V with miniaturized electrodes. 
A) A small cells (black arrow) enter the channel in front of a larger cells (blue arrow). 
The larger cells is approximately twice of the size of the small cell. B) The large cell 
moving faster and shorten the distance between them. C) The large cells catch up with the 
small cells. D) The large cells moving past the small cell.  
Conclusion 
 The innovation of this study has important practical applications. The technical 
and clinical innovations of this study could lead to a fundamental change of cancer 
treatment. The clinical innovation of using CTC for cancer diagnosis and treatment 
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evaluation is expected to deliver more effective therapies, yet to do this you have to 
successfully separate CTC from the other cells. This would be one step closer to the goal 
of personalized medicine, where treatments are designed for the individual and not for 
how the group reacts.  
Obviously, electrolytic flow systems significantly change the local concentration 
of ions, as these respond to the applied electrical fields.72-75 Indeed, this is the basic 
principle behind electrophoresis, a widely used method to sort ions, bacteria, and cells by 
their mobility for countless applications.76-81 However, this ion segregation effect also 
limits the use of continuous electrical current in devices where the ion concentration 
should remain unaltered. As a solution to avoid ionic segregation, pulsed or alternating 
current electrophoresis methods have been developed in the past. These systems, 
operating at frequencies into the MHz range, have been used to demonstrate 
dielectrophoresis, sorting of particles by size and dielectric constant.81-83 For improved 
control over the molecules, viscous fluids such as gels are often used. Another 
consequence of applying an electrical field onto ionic solutions is that above the 
dissociation potential of water of approximately 2.03V, evolution of hydrogen and 
oxygen gas occurs at the electrodes, and often bubbles from within microfluidic systems. 
This effect is commonly an unwanted problem, as these small gas bubbles often block the 
flow of liquids through the system.  
However, both ion segregation and electrolytic dissociation can be addressed by 
miniaturizing devices and completely integrating the system within either an SOI or 
PDMS based fluidic devices, for the sorting of live mammalian cells (i.e., CTCs). While 
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this is not the first time that such an approach was used to move cells, by combining 
electric movement with nanofabrication capabilities and integrated electrodes within the 
microfluidic system for single-cell sorting, this system does not require a large amount of 
external control hardware. The resulting devices, with minimal external interfaces, will 
be able to be readily controlled from electronic devices, such as laptops and cellphones, 
and will be able to be deployed in applications where more conventional fluidic systems 
monitored with fluorescent microscopes cannot function.  
I have built a prototype device to demonstrate the operation principle of our 
proposed platform. As shown in Figure 5.14, a microfluidic channel in PDMS was bound 
to the rows of miniaturized chromium electrodes. Applying 0.2V to these miniaturized 
electrodes generates an electrophoretic flow to move live cells in PBS. The applied low 
voltages did not generate any electrolytic gas as we do not exceed the hydrogen evolution 
potential. As we use many electrodes, and apply voltages across these in sequence, the 
ion segregation typically associated with electrophoretic systems is avoided. The ion 
chemistry in our flow channels will remain relatively constant, as diffusion is allowed to 
redistribute the ions between applied electrical pulses. We also observe that cells with 
different sizes are moving at different speeds, proportional to their crossectional areas. 
Larger size cells move faster than smaller size cells, as demonstrated in Figure 5.14, 
which thus represents a cell sorting mechanism.  
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Chapter 6 
Persistence Length Quantitative Polymerase Chain Reactions Using Quenchiplexing 
and FRETplexing 
 
 
Introduction 
 
Cancer is a group of genetic diseases that is poised to overtake cardiovascular 
diseases as the leading cause of death in the world, largely due to the aging population in 
the world. In the US alone, there are over 600,000 new cases and 250,000 deaths per year 
98 and the four leading cancers, lung, breast, pancreatic, and colorectal, contribute 
significantly to the amount of the new cases and deaths. Hundreds of billions of dollars 
have been used combat cancer in both research and drug development, and as a result a 
wide array of therapies and drugs were developed, yet it has only been in the past ten 
years that targeted therapies have established themselves as powerful and effective tools 
that increase a patients’ longevity and avoid the side effects and morbidity of 
conventional chemotherapy. The advent of targeted therapy comes from the idea that 
since cancer is a genetic condition, most individual’s cancers result from a combination 
of specific and unique mutations. Old cancer treatments were general to specific cancers; 
however, therapies work on specific pathways, which can be circumvented by certain 
mutations, leading to drug resistance. As a result, extremely expensive drugs 99 fail to 
benefit a significant portion of the patients100-102, thereby wasting health care resources 
and decreasing the patients’ overall chances of survival. Systematic detailed genetic 
analysis of tumors, combined with a knowledge of the mutations critical to drug 
resistance, can answer this problem, but it comes with a increase in cost and time to 
treatment. Currently there are no techniques that simultaneously possess the necessary 
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affordability, coverage, speed, throughput, specificity, and sensitivity to provide such 
tissue analysis on a routine clinical basis.  
To answer this challenge, I have helped to develop and provided two novel 
techniques called quenchiplexing and FRETplexing. Current methods for identifying 
nucleic acid targets involve using intercalating fluorophores or nucleic acid probes. For 
instance, conjugating fluorescent dyes and quenchers onto short sequence nucleic acids 
allows for specific, fluorogenic tagging of nucleic acids. This technique is commonly 
used, and is the mechanism of action for hydrolysis probes (such as TaqMan and FRET) 
and molecular beacons. If a target sequence is present, its probes and primers will 
hybridize to it. As the polymerase extends the primer, the 5’ exonuclease activity of the 
Taq polymerase breaks the probe sequence. This separates the fluorophore from the 
quencher and generates a strong positive signal.  Similar signals can be generated using 
molecular beacons, which are short pieces of DNA that have a fluorophore conjugated to 
the 5’ end and a quencher conjugated to the 3’ end. At lower temperatures molecular 
beacons form hairpin structures that bring the fluorophore and quencher into close 
proximity. The FRET effect inhibits fluorescence even while the fluorophores are being 
pumped. When heated, the beacon unravels and is free to hybridize with the target 
sequence. As this hybridization occurs, the fluorophore is separated from its short strand 
nucleic acids, generating a strong signal. 
Both of these new methods utilize automated PCR and the information acquired 
from a PCR machine. Under a traditional PCR method, primers are used to amplify a 
given piece of DNA. These pieces of DNA can be specific for general amplification 
primers. After the reaction has finished its amplification cycles, the accumulated data 
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appears as documented in Figure 6.1. Unfortunately, in the case of many reactions, since 
the label is general, the only information that is generated is knowledge that something in 
the reaction was amplified, or you need to add an additional specific label to determine if 
one specific target was amplified. With these new methods there is no need for the 
addition of an additional specific label, you acquire the specific information from the 
primers themselves and it is even possible to generate other data from the PCR reaction, 
beside just DNA amplification. To test this system I used the six most common mutations 
found in KRAS that contribute to colorectal cancer. 
 
Figure 6.1. Iconic PCR graph. 
KRAS Mutations in Colorectal Cancer (CRC) is responsible for 140,000 new cases and 
49,000 deaths per year in the US alone98. One of the most effective and widely used 
drugs against CRC is Cetuximab, which is a $1.75B/yr industry in the world99. However, 
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KRAS mutations lead to resistance to Cetuximab100-102 in at least 35% of the patients. As 
a result, the American Society of Clinical Oncology (ASCO) issued a recommendation in 
2009 that patients need to be tested for KRAS mutations before being prescribed the 
drug, with projected net savings of $753M per year worldwide103. However, half of the 
patients that test negative by traditional allele-specific assays still fail the 8-week $30,000 
regimen. Hence, new and more sensitive techniques are necessary to ensure proper 
stratification of patients. Thus, this technique would have a major clinical utility. 
Furthermore, KRAS mutations are SNP’s, which are perfectly suited for PCR systems. 
Hence, KRAS in CRC is the ideal system for the proof of principle.  
Material and Methods 
Primer design 
 A pair of forward and reverse primers is constructed to be specific to a 
corresponding target sequence, which was determined by using the NIH gene BLAST 
program and is designed to function at reaction conditions of q-PCR. In general, the 
primers can be selected to ensure that the forward and reverse primers are specific to the 
corresponding target sequence and have similar melting temperatures (preferably within 1 
or 2 °C from each other and no more than 5°C) so that specific hybridization and 
extension of both forward and reverse primers takes place under the same reaction 
conditions in the reaction mixture. Using the reaction conditions of commercially 
available q-PCR kits, primers can be typically between 20 to 35 bp long to allow for 
enough specificity at the related melting temperatures. When the target sequence includes 
a SNP or point mutation, the primers typically have the 3’ end base overlapping the point 
mutation to maximize sensitivity. In particular, for detection of a SNP a base 
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complementary to the expected SNP in the target sequence is included in the primer at 
the 3’ end of the primer within a range of 1 to 3 bp from such 3’ end towards the 5’ end 
direction, preferably at the 3’ terminus.  
 A similar approach can be used for a different variation of a reference 
polynucleotide analyte, e.g., a mutation, deletion, or insertion, wherein the primers can be 
designed so that they specifically bind to a target sequence where the expected variation 
might be located in one or more consecutive base pairs that are indicative of the variation. 
In particular, the primers are designed to specifically bind to the sequence indicative of 
the variation, preferably with their 3’ end. 
All oligonucleotides were synthesized by Integrated DNA Technologies 
(Coralville, Iowa). Diagnostic sequences were input into IDT’s OligoAnalyzer 3.1 tool. 
Probes and primer pairs for each target were chosen, from the OligoAnalyzer’s set of 
generated sequences, to minimize homology with un-intended targets, probes, and 
primers. Forward primers for all targets were synthesized with a fluorophore at the 5’ 
end, while the reverse primes for all targets were synthesized with a quencher at the 5’ 
end for quenchiplexing or a complement fluorophore for FRETplexing. Sequence 
information is tabulated in Tables 6.1 and 6.3. Nucleic acid products were synthesized 
and lyophilized by IDT. These products were reconstituted with TE buffer and aliquoted 
for experimental use. All nucleic acid targets were reconstituted in TE buffer, ph 7.0 
(Life Technologies, Carlsbad, CA). Dilutions were made using UltraPure RNAse-free 
Water (Life Technologies, Carlsbad, CA). 
 
Assay Development 
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In the novel method quenchiplexing the same principles governing fluorophore -
quencher interactions can be used to identifying nucleic acids based on persistence 
length. In this novel technique, called “quenchiplexing”, specific forward (FWD) and 
reverse (RWD) primers with fluorophores and quenchers, respectively, were designed for 
a particular target, and this target can be a virus, gene, RNA, or SNP. As the target is 
amplified with successive cycles of a polymerase chain reaction, the fluorophores and 
quenchers get incorporated into the template strands (Figure 6.2) and generate a FRET or 
quenching signal (Figure 6.3 and 6.4). In the Figure 6.2, f is the fluorophore label 
attached to a primer and q is the quencher label attached to a primer and in the case of 
FRETplex the quencher label is replaced with a complement fluorophore label to 
generate a FRET signal.  
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Figure 6.2. Quenchiplexing PCR Procedure. 
As the length of the template strand is known (it is defined by the locations of the 
forward and reverse primers), the extent of the quenched fluorescence will be fixed for a 
particular target. This technique will work as long as the separation between the 
  
102 
fluorophore and quencher is within the Förster radius of the quencher. After several 
cycles of a PRC cycle occur, if the desired target is present, the fluorphore tagged primer 
generated amplicon will hybridize with the quencher tagged primer, resulting in a 
reduction in fluorescent intensity in a target specific inverse PCR amplification graph 
(Figure 6.2). 
In a similar but also novel method, FRETplex quenchers are replaced with 
another fluoraphore. When the primer pairs are designed to attach to a donor and acceptor 
of a FRET donor-acceptor chromophore pair, and to specifically bind to target sequences 
within one or more target polynucleotides, the primers specifically bind to the 
corresponding target sequence; the primers present the FRET donor and acceptor at a 
distance up to four times the Förster distance for that FRET donor-acceptor chromophore 
pair. 
Both methods exploit florescent intensity in generating data. Under normal PCR 
methods (Figure 6.1) amplification occurs when primers interact with a target sequence. 
In quenchiplexing, the florescent intensity is uniform (straight line) when no target is 
present; this is the result of no DNA hybridization to allow quenchers and fluoraphores to 
hybridize to each other, yet when the specific target is present the forward and reverse 
primer can hybridize together and cause a drop in the fluorescent signal (delta blue arrow 
in Figure 6.3), signifying the presence of the target analyte. In FRETplexing, in the 
absence of a specific target no fluoresces is observed, since the forward and reverse 
primes are unable to hybridize to each other, generating no signal, yet in the presence of 
the target the primers are able to hybridize together resulting in a FRET signal (Figure 
6.4), where the delta displayed as the blue arrow in the figure is the change in fluoresce 
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over the background signal. 
 
Figure 6.3.Example of Quenchiplexing PCR Result. 
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Figure 6.4. Example of FRETplexing PCR Result. 
Using a standard RT-PCR machine I can perform multiplexed allelic-specific 
PCR assays that offer higher specificity and higher throughput, as multiple mutations 
would be identifiable simultaneously in each chamber. Assembling the fluorescence 
signals from each chamber would produce a high-resolution map that correlates the 
morphology with the genetic makeup of the KRAS mutation present in the sample. This 
mapping would allow for accurate and reliable stratification of patients.  
PCR Multiplexing 
State-of-the-art PCR coding is typically limited to one target per color for four 
colors, due to the spectral overlap of standard fluorophores. Some attempts [11-13] have 
been made to breach that barrier and code for more targets than available colors, but 
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those methods invariably bumped into the degeneracy problem: if more than one target 
sequence is present, the decoding is no longer unique, so the answer is ambiguous and 
generally useless. Our multiplexing technology [1] is the first to breach the supercolor 
barrier while ensuring completely non-degenerate and unambiguous decoding for any 
combination of targets present. In practical terms, it offers easy access to at least a 48-
plex assay, compared to a maximal 3-plex under conventional coding. How the multiplex 
detection method works is that it can combine the use of color, multiplicity of signal 
intensity, and/or mathematical strategies to circumvent degeneracy and ensure an infinite 
number of unique codes that can be unambiguously decoded in any combination of 
occurrences. For example, in detecting a sample containing four analytes, each analyte 
can be assigned a fluorophore (blue, green, yellow, or red) and a quencher attached to 
analyte-specific oligonucleotides (e.g., a forward PCR primer and a reverse PCR primer). 
Upon amplification, the presence or absence of an analyte is determined based on the 
presence or absence of a signal in that particular color.  Another example is based on 
color intensity, where each analyte is assigned a fluorescent intensity (1x, 2x, 4x etc), 
where 1x is the concentration of labeled primers used, and where combining the intensity 
generates a readable code that can be used to determine the presents of a given analyte. 
By taking the delta of a PCR reaction (blue arrow in Figure 6.3 and 6.4) we generate a 
fluorescent intensity, which ends up as linear combination of florescent intensities (1x 
plus 2x equals 3x, 4x plus 1x equals 5x); thus, this method is an important technological 
advance.  
Allele-specific assays typically offer only one mutation to be identified per 
sample. The reason is that fluorophores have a wide emission spectra, which overlap and 
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cause false positives if more than four colors are used simultaneously. Thus, a mutation 
plus a positive control would take two of the available four colors. This is a severe 
restriction, especially since many mutations of the same gene can occur in the same 
sample. For example, there are at least eight KRAS mutations [9, 10] leading to drug 
resistance in colorectal cancer. As a stopgap measure, some commercial assays sacrifice 
identification and code multiple mutations in the same color, the rationale being that any 
targeted mutations present would produce a positive result and thus would mean drug 
resistance. However, this is woefully inadequate as mutation identification is critical in 
fundamental research and in the careful clinical stratification of patients. In contrast, 
using FRETplexing or quenchingplex methods multiple mutations can unambiguously be 
identified in each color or intensity together with a morphological confirmation, 
including with superior specificity and sensitivity.  
Polymerase chain reactions 
 
All PCR reactions were performed on a Roche 480 LightCycler I and II 
instrument (Roche Applied Science, Penzberg, Germany). The PCR cycling reaction was 
run for a minimum of 45 cycles, with a 180 sec hot-start at 95°C. The cycling conditions 
were as follows: denaturation for 10 sec at 95°C, annealing for 50 sec at 50°C, and 
detection for 12 sec at 72°C. Each experiment was run in groups of 12, with a reaction 
volume of 15µL. Fluorescence measurements in 523nm-568nm (Cy3) and 615nm-670nm 
(Cy5) were taken at the end of annealing for every cycle for quenchiplex and excitation at 
498nm with detection at 610-640nm for FRETplexing. The change in fluorescence 
intensity between the first and last measurements, for each instance of an experiment, 
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determined the quenched or FRET signal. Furthermore, a melt curve measurement was 
taken every degree between 58°C and 70°C.  
 
 Positive control experiments were performed to determine base-line quenching 
and FRET levels for each target and set of primers. The change in fluorescence intensity 
was used to assemble the expected cumulative signal levels in the delta graphs (example 
in Figure 6.4 and results Figure 6.25). In each case, the higher intensity count 
corresponded to a unique combination of present targets. The baseline concentration for a 
1x count was determined by a set of fluoraphore titration experiments. A 200nM 1x 
concentration of probes in the FAM channel allowed for a sufficiently strong signal that 
minimized cross-channel bleed through. The expected multiplicative signal levels were 
determined by multiplying this baseline by the multiplicity. 
 
Results 
Quenchiplexing 
 When trying to establish a new method there is no guarantee that the system will 
actually function as intended. Groups of STI were ordered to test the system (as seen in 
table 6.1). No parameters were determined yet the system was run using the parameters in 
table 6.2. Lamda DNA with primers was barrowed form David Baltimore to use as a 
control to determine if the PCR was functioning properly. The initial test result, displayed 
in Figure 6.5, revealed that the quechiplexing assay does function properly, and the data 
from the PCR machine appears to be a inverse PCR graph. With the knowledge that the 
system functions I started to develop an assay to test for SNPs found in K-RAS 
mutations. 
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STI Sequence Forward Primer Reverse Primer 
Chlamydia CAT TAG GAT TTA CGA 
AGG ATG GGA AGG TTT 
AAC TGA CGA AGA AAA 
TAT AGA TAT AGA CTT 
AAC ACC TTT TAA TTC ACC 
AC 
/5Cy3/CAT 
TAG GAT TTA 
CGA AGG ATG 
GGA AGG TTT 
/5IABkFQ/GTG 
GTG AAT TAA 
AAG GTG TTA 
AGT CTA TAT 
CTA TAT TTT 
CTT 
HIV pol AGC TAT AGG TAC AGT 
ATT AGT AGG ACC TAC 
ACC TGT CAA CAT AAT 
TGG AAG AAA 
/5Cy3/AGC 
TAT AGG TAC 
AGT ATT AGT 
AGG ACC TAC 
ACC 
/5IABkFQ/AAG 
TGC AAC CAA 
TCT GAG TCA 
ACA GAT TTC 
Gonorrhea TTT CAA AGA AGC GCC 
TAT GCT GGT GCG CTC TTA 
CGC TGC CGC CAT CAA 
ACG TCG CTA CAT CCA 
AGT CAA TCC GTC GCA TC 
/5Cy3/TTT 
CAA AGA AGC 
GCC TAT GCT 
GGT 
/5IABkFQ/GAT 
GCG ACG GAT 
TGA CTT GGA 
TGT 
Syphilis GAA GGG AAG CAG GTG 
TAG TCA TGG CGA CGG 
GAA ATA CTG TCT AAG 
GTT AGG TTG CAA GAG 
ACC GTA CCG CAA ACC 
GAC AC 
/5Cy3/GAA 
GGG AAG CAG 
GTG TAG TCA 
TGG 
/5IABkFQ/GTG 
TCG GTT TGC 
GGT ACG G 
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HIV gag TTA ATC CTG GCC TGT TAG 
AAA CAT CAG AAG GCT 
GTA GAC AAA TAC TGG 
GAC AGC TAC AAC CAT 
CCC TTC AGA CAG GAT CA 
/5Cy3/GCC 
TTC TGA TGT 
TTC TAA CAG 
GCC AGG ATT 
AA 
/5IABkFQ/TGA 
TCC TGT CTG 
AAG GGA TGG 
TTG 
Herpes 
Virus 2 
TTC CGG CCG ACA CCC 
AGG AAA CAA CGA CGC 
GCC GGG CCC TTT ATA 
AAG AGA TAC GCG ATG 
CGT TGG GCA GTC GAA 
AAC AG 
/5Cy3/TTC 
CGG CCG ACA 
CCC A 
/5IABkFQ/CTG 
TTT TCG ACT 
GCC CAA CGC 
Table 6.1.Sequence and Primers of STI Initial Test Panel for Quenichiplexing Assay 
Development. 
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Figure 6.5. Initial PCR Machine Readout for he STI Test Experiment. 
 
STI’s Sequence 
10uM 
Forward 
Primer 
10uM 
Reverse 
Primer 
10um 
Taq Master 
Mix 
5x 
H2O 
Volume 20uL 4uL 4uL 40uL 132uL 
Table 6.2. Experimental Volumes and Concentrations used for the STI Initial 
Experimental Test. 
 
Using the literature on the most common point mutations found in K-RAS related 
cancer and the NIH BLAST program, I designed specific forward primers for the top six 
most common point mutations (Tables 6.3 and 6.4), and used a generic reverse primer for 
all mutations, and wild type and mutant sequences for the first 99bp of the K-RAS gene. 
After several experiments to determine the lowest visible primer concentration (data not 
included) it was concluded that the lowest concentration visible was too low for reliable 
pipetting; as a result, the lowest primer volume used was 2uL, and because this is the 1x 
concentration, the 2x concentration is 4uL, 4x becomes 8uL, and so on till the system 
becomes saturated. 
 
 
WT/Mutants Sequence 
WT 
 
5’- ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GGT 
GGC GTA GGC AAG AGT GCC TTG ACG ATA CAG CTA ATT 
CAG AAT CAT TTT GTG GAC -3’ 
216A  
5’- ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GAT 
GGC GTA GGC AAG AGT GCC TTG ACG ATA CAG CTA ATT 
CAG AAT CAT TTT GTG GAC -3’ 
216T 
5’- ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GTT 
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WT/Mutants Sequence 
GGC GTA GGC AAG AGT GCC TTG ACG ATA CAG CTA ATT 
CAG AAT CAT TTT GTG GAC -3’ 
216C 
5’- ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GCT 
GGC GTA GGC AAG AGT GCC TTG ACG ATA CAG CTA ATT 
CAG AAT CAT TTT GTG GAC -3’ 
219A 
5’- ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GCT 
GAC GTA GGC AAG AGT GCC TTG ACG ATA CAG CTA ATT 
CAG AAT CAT TTT GTG GAC -3’ 
215A 
5’- ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT ACT 
GGC GTA GGC AAG AGT GCC TTG ACG ATA CAG CTA ATT 
CAG AAT CAT TTT GTG GAC -3’ 
215T 
5’- ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT TCT 
GGC GTA GGC AAG AGT GCC TTG ACG ATA CAG CTA ATT 
CAG AAT CAT TTT GTG GAC -3’ 
 
Table 6.3. Sequences Used for KRAS Mutation Experiments 
KRAS 
mutation 
Forward Primer Reverse primer 
generic for all 
mutations 
Reverse Primers 
2nd generation 
216T / 5Cy3 
/GAATATAAACTTGT
GGTAGTTGGAGCTGT 
/5IABkFQ/GTC 
CAC AAA ATG 
AAT CTG AAT 
TAG CTG 
/ 5lABkFQ/ 
GTCCACAAAAT
GAATCTGAAT 
216C / 5Cy3 
/GAATATAAACTTGT
GGTAGTTGGAGCTG
C 
 / 5lABkFQ 
/GTCCACAAAAT
GAATCTGAAT 
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KRAS 
mutation 
Forward Primer Reverse primer 
generic for all 
mutations 
Reverse Primers 
2nd generation 
219A / 5Cy3 
/GAATATAAACTTGT
GGTAGTTGGAGCTG
GTGA 
 / 5lABkFQ 
/GTCCACAAAAT
GAATCTGAAT 
216A /5Cy3/GAATATAAAC
TTGTGGTAGTTGGAG
CTGA 
 /5IABkFQ/GCA 
CTC TTG CCT 
ACG CCA T 
215T /5Cy3/GAATATAAAC
TTGTGGTAGTTGGAG
CTT 
 /5IABkFQ/CAC 
TCT TGC CTA 
CGC CAC A 
215A /5Cy3/GAATATAAAC
TTGTGGTAGTTGGAG
CTA 
 /5IABkFQ/CAC 
TCT TGC CTA 
CGC CAC T 
Table 6.4. Sequence and Primers of KRAS Test Panel for Quenichiplexing Assay 
Development. 
 
 
 Using the sequence information in Table 6.3 and the primer information from 
Table 6.4, K-RAS experiments were designed to test the ability of quenchiplexing to 
identify specific point mutations in the PCR machine. With the experimental design 
found in Table 6.5, each STI concentration was run independently with 24 replicates. The 
data from these experiments is found in Figure 6.6-6.11. Although the intensity scales in 
all the figures, which is expected in a intensity multiplexing assay, the quenchiplexing 
assay as currently designed was unsuccessful. The initial problem was the experimental 
and reverse primer design; by design a generic reverse primer that can hybridize with 
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both the mutant and wild type sequence was problematic. Even though the forward 
primer was specific and could only amplify at mutant sequence, the reverse primer was 
amplifying both the mutant and wild type sequences. This would most likely contribute to 
the linear quenching observed in Figures 6.6-6.11. Using the data from these experiments 
the reverse primer was redesigned to the 2nd generation reverse primer found in table 6.4. 
 
STI 
Concentratio
n 
Mutant 
Sequence 
Forward 
Primer 
Reverse 
Primer 
Taq 5x 
Master 
Mix 
H2O Wild 
Type 
Sequence 
1x 10uL 2uL 2uL 20uL 66uL 10uL 
2x 10uL 4uL 4uL 20uL 62uL 10uL 
4x 10uL 8uL 8uL 20uL 54uL 10uL 
8x 10uL 16uL 16uL 20uL 38uL 10uL 
Table 6.5. Experimental Protocol for KRAS Quenchiplexing Experiment. 
 
 
 
Figure 6.6. Quenchiplexing KRAS 216T at 1x Concentration. The chart shows averaged 
fluorescence emission signal of 18 qPCR replica experiments (at y-axis) plotted as a 
function of PCR cycles with a standard deviation of 1σ. 
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Figure 6.7. Quenchiplexing KRAS 216T at 2x Concentration. The chart shows averaged 
fluorescence emission signal of 18 qPCR replica experiments (at y-axis) plotted as a 
function of PCR cycles with a standard deviation of 1σ. 
 
Figure 6.8. Quenchiplexing KRAS 216T at 4x Concentration. The chart shows averaged 
fluorescence emission signal of 18 qPCR replica experiments (at y-axis) plotted as a 
function of PCR cycles with a standard deviation of 1σ. 
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Figure 6.9. Quenchiplexing KRAS 216T at 1x, 2x, and 4x Concentration. The chart 
shows averaged fluorescence emission signal of 18 qPCR replica experiments (at y-axis) 
plotted as a function of PCR cycles with a standard deviation of 1σ. 
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Figure 6.10. Quenchiplexing KRAS 216A at 1x, 2x, 4x, and 8x Concentration. The chart 
shows averaged fluorescence emission signal of 18 qPCR replica experiments (at y-axis) 
plotted as a function of PCR cycles with a standard deviation of 1σ. 
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Figure 6.11. Quenchiplexing KRAS 216C at 1x, 2x, 4x, and 8x Concentration. The chart 
shows averaged fluorescence emission signal of 18 qPCR replica experiments (at y-axis) 
plotted as a function of PCR cycles with a standard deviation of 1σ. 
 
Using the information acquired from the failed quechiplexing experiment new 
experiments were designed, as seen in Tables 6.6-6.8. The same PCR and replicates were 
used as the prior experiment, and the only change is the reverse primer. The resulting 
data was used to generate Figures 6.13-6.14. Unlike the earlier experiments there is more 
of an iconic inverse PCR graph generated, which is the desired result. When examining 
the deltas of each graph, values of 0.4A.U for 1x concentration, 0.8A.U. for 2x 
concentration and around 1.6A.U for 4x concentration are generated. This proves that the 
quenchiplexing assay works and it is possible to use intensity coding with quenchiplexing 
for multiplexing assays. With the assay validated to perform as designed, experiments 
were performed to test the combination of mutation concentrations to generate the 3x, 5x, 
6x, and 7x concentrations, which should result by adding the different primer 
combinations together. 
Components  Volume (uL)/Concentration(uM) 
Reagents  20uL of 100 uM Taq 5x matermix 
WT 10uL of 100uM 
216C 10uL of 10uM  
216C primer 1× 2 uL of 10uM forward and reverse primer 
Table 6.6. Experiment Cocktail for Quenchiplexing Detection of a Single 216C Mutation. 
 
Components  Volume (uL)/Concentration(uM) 
Reagents  20uL of 100 uM Taq 5x matermix 
WT 10uL of 100uM 
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Components  Volume (uL)/Concentration(uM) 
216T  10uL of 10uM  
216T primer 2× 4 uL of 10uM forward and reverse primer 
Table 6.7. Experiment Cocktail for Quenchiplexing Detection of a Single 216T Mutation. 
 
Components  Volume (uL)/Concentration(uM) 
Reagents  20uL of 100 uM Taq 5x matermix 
WT 10uL of 100uM 
216A  10uL of 10uM  
216A primer 4× 48uL of 10uM forward and reverse primer 
Table 6.8. Experiment Cocktail for Quenchiplexing Detection of a Single 216A Mutation. 
 
 
Figure 6.12. Improved Quenchiplexing Assay for 216C at 1x Concentration. Chart 
reporting detection of 216C mutant sequence from the KRAS gene using quenchiplexing 
with qPCR. The multiplexed assay contains 0.5uL of 10uM forward and reverse primer 
concentration, 20uL of Taq 5x matermix, and 10uL of 10uM mutant 216C.  The forward 
primer is labeled with Cy3 as a fluorophore and the reverse primer is labeled with 
lABkFQ as a quencher. The chart shows averaged fluorescence emission signal of 12 
qPCR replica experiments (at y-axis) plotted as a function of PCR cycles with a standard 
deviation of 1σ. The amplification phase starts at cycle 8 and the saturation phase at cycle 
18. 
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Figure 6.13. Improved Quenchiplexing Assay for 216T at 2x Concentration. Chart 
reporting detection of 216T mutant sequence from the KRAS gene using quenchiplexing 
with qPCR. The multiplexed assay contains  1uL of 10uM forward and reverse primer 
concentration, 20uL of Taq 5x matermix, and 10uL of 10uM mutant 216T. The forward 
primer is labeled with Cy3 as a fluorophore and the reverse primer is labeled with 
lABkFQ as a quencher. The chart shows averaged fluorescence emission signal of 12 
qPCR replica experiments (at y-axis) plotted as a function of PCR cycles with a standard 
deviation of 1σ. 
 
Figure 6.14. Improved Quenchiplexing Assay for 216A at 4x Concentration.  Chart 
reporting detection of 216A mutant sequence from the KRAS gene using quenchiplexing 
with qPCR. The multiplexed assay contains 2uL of 10uM forward and reverse primer 
concentration, 20uL of Taq 5x matermix, and 10uL of 10uM mutant 216A. The forward 
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primer is labeled with Cy3 as a fluorophore and the reverse primer is labeled with 
lABkFQ as a quencher. The chart shows averaged fluorescence emission signal of 12 
qPCR replica experiments (at y-axis) plotted as a function of PCR cycles with a standard 
deviation of 1σ. 
 By slightly modifying the experimental reagents I combined multiple mutations in 
a single reaction to observe the multiplexing behavior of the assay. The experimental 
protocols are displayed in Tables 6.9-6.12 and the resulting data is graphed in figures 
6.15-6.18. Similar to the first failed experiments, there is a loss of the iconic inverse PCR 
graph (Figures 6.15-6.18). The theory behind why the experiment failed is a unique case 
for this system; all the sequences and primers share a high degree of similarity, with just 
one or two base pair difference, and as a result it is difficult for primers to hybridize with 
the correct target due to the high degree of similarity.  As the PCR experiment proceeds 
this problem only increases, since there are more sequences to hybridize and the 
probability of finding the correct target gets further reduced. In addition to the statistical 
problem, the high degree of similarity will not encourage the incorrect sequence to 
decouple with the incorrect target. This would not be a problem with the STI sequences 
tested earlier, since their sequences have a low level of similarity, yet for KRAS 
mutations and the sequences similarity, this is problematic. Even with these problems the 
assays high degree of specificity, when amplifying a target sequences, provided a useful 
diagnostic application for this assay. 
 
Components  Concentration Volume 
Reagents  100uM 20uL 
WT 100uM 10uL 
216C 10uM 10uL 
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216T 10uM 10uL 
216T Primer 10uM 4uL 
216C Primer 10uM 2uL 
Table 6.9. Experiment Cocktail for Quenchiplexing Detection of a Double Mutation 
216T at 2× and 216C at 1× Primer Concentrations. 
 
Components  Concentration Volume 
Reagents  100uM 20uL 
WT 100uM 10uL 
216T 10uM 10uL 
216A 10uM 10uL 
216T Primer 10uM 4uL 
216A Primer 10uM 8uL 
Table 6.10. Experiment Cocktail for Quenchiplexing Detection of a Double Mutation 
216T at 2× and 216A at 4× Primer Concentrations. 
 
Components  Concentration Volume 
Reagents  100uM 40uL 
WT 100uM 10uL 
216C 10uM 10uL 
216A 10uM 10uL 
216C Primer 10uM 2uL 
216A Primer 10uM 8uL 
Table 6.11. Experiment Cocktail for Quenchiplexing Detection of a Double Mutation 
216C at 1× and 216A at 4× Primer Concentrations. 
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Components  Concentration Volume 
Reagents  100uM 40uL 
WT 100uM 10uL 
216C 10uM 10uL 
216T 10uM 10uL 
216A 10uM 10uL 
216T Primer 10uM 4uL 
216C Primer 10uM 2uL 
216A Primer 10uM 8uL 
Table 6.12. Experiment Cocktail for Quenchiplexing Detection of a Triple Mutation 
216T at 2× and 216C at 1× and 216A at 4× Primer Concentrations. 
 
 
Figure 6.15. Improved Quenchiplexing Assay for 216C at 1x and 216T at 2x 
Concentration.  Chart reporting detection of 216C and 216T mutant sequence from the K-
RAS gene using quenchiplexing with qPCR. The multiplexed assay contains 0.5uL of 
10uM forward and reverse primer concentration for 216C, 1uL of 10uM forward and 
reverse primer concentration for 216T, 20uL of Taq 5x matermix, 10uL of 10uM mutant 
216C, and 10uL of 10uM 216T. The forward primer is labeled with Cy3 as a fluorophore 
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and the reverse primer is labeled with lABkFQ as a quencher. The chart shows the  
averaged fluorescence emission signal of 12 qPCR replica experiments (at y-axis) plotted 
as a function of PCR cycles with a standard deviation of 1σ. 
 
Figure 6.16.Improved Quenchiplexing Assay for 216C at 1x and 216A at 4x 
Concentration.  Chart reporting detection of 216C and 216A mutant sequence from the 
K-RAS gene using quenchiplexing with qPCR. The multiplexed assay contains 0.5uL of 
10uM forward and reverse primer concentration for 216A, 2uL of 10uM forward and 
reverse primer concentration for 216T, 20uL of Taq 5x matermix, 10uL of 10uM mutant 
216C, and 10uL of 10uM 216A. The forward primer is labeled with Cy3 as a fluorophore 
and the reverse primer is labeled with lABkFQ as a quencher. The chart shows the  
averaged fluorescence emission signal of 12 qPCR replica experiments (at y-axis) plotted 
as a function of PCR cycles with a standard deviation of 1σ.   
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Figure 6.17.Improved Quenchiplexing Assay for 216T at 2x and 216A at 4x 
Concentration. Chart reporting detection of 216T and 216A mutant sequence from the K-
RAS gene using quenchiplexing with qPCR. The multiplexed assay contains 1uL of 
10uM forward and reverse primer concentration for 216T, 2uL of 10uM forward and 
reverse primer concentration for 216A, 20uL of Taq 5x matermix and 10uL of 10uM 
mutant 216T, and 10uL of 10uM 216A. The forward primer is labeled with Cy3 as a 
fluorophore and the reverse primer is labeled with lABkFQ as a quencher. The chart 
shows the averaged fluorescence emission signal of 12 qPCR replica experiments (at y-
axis) plotted as a function of PCR cycles with a standard deviation of 1σ. 
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Figure 6.18.Improved Quenchiplexing Assay for 216C at 1x, 216T at 2x, and 216A at 4x 
Concentration. Chart reporting detection of 216C, 216T, and 216A mutant sequence from 
the KRAS gene using quenchiplexing with qPCR. The multiplexed assay contains 0.5uL 
of 10uM forward and reverse primer concentration for 216C, 1uL of 10uM forward and 
reverse primer concentration for 216T, 2uL of 10uM forward and reverse primer 
concentration for 216A, 20uL of Taq 5x matermix, and 10uL of 10uM for each mutant 
216C, 216T, and 216A. The forward primer is labeled with Cy3 as a fluorophore and the 
reverse primer is labeled with lABkFQ as a quencher. The chart shows the  averaged 
fluorescence emission signal of 12 qPCR replica experiments (at y-axis) plotted as a 
function of PCR cycles with a standard deviation of 1σ.   
Table 6.13. Sequences of Primers for KRAS FRETplexing Assay Development. 
 
KRAS mutation Forward Primer Reverse 
Primers 1st 
generation 
Reverse Primers 
2nd generation 
Reverse Primers 
3rd generation 
216A 
 
/5Cy3/GAATATAA
ACTTGTGGTAGTT
GGAGCTGA 
/5Cy5/GCACT
CTTGCCTAC
GCCAT 
/56-FAM/AAT ATA 
AAC TTG TGG 
TAG TTG GAG 
CTG A 
/5LtC640N/GCA CTC 
TTG CCT ACG CCA 
T 
216T /5Cy3/GAATATAA
ACTTGTGGTAGTT
GGAGCTGT 
/5Cy5/GCACT
CTTGCCTAC
GCCAA 
/56-FAM/AAT ATA 
AAC TTG TGG 
TAG TTG GAG 
CTG T 
/5LtC640N/GCA CTC 
TTG CCT ACG CCA 
A 
216C /5Cy3/GAATATAA
ACTTGTGGTAGTT
GGAGCTGC 
/5Cy5/GCACT
CTTGCCTAC
GCCAG 
/56-FAM/AAT ATA 
AAC TTG TGG 
TAG TTG GAG 
CTG C 
/5LtC640N/GCA CTC 
TTG CCT ACG CCA 
G 
219A /5Cy3/GAATATAA
ACTTGTGGTAGTT
GGAGCTGGTGA 
/5Cy5/TCAAG
GCACTCTTG
CCTACGT 
/56-FAM/AAT ATA 
AAC TTG TGG 
TAG TTG GAG 
CTG GTG A 
/5LTC640N/GCA 
CTC TTG CCT ACG 
T 
215A /5Cy3/GAATATAA
ACTTGTGGTAGTT
GGAGCTA 
/5Cy5/CACTC
TTGCCTACG
CCACT 
/56-FAM/AAT ATA 
AAC TTG TGG 
TAG TTG GAG 
CTA 
/5LTC640N/GCA 
CTC TTG CCT ACG 
CCA CT 
215T /5Cy3/GAATATAA
ACTTGTGGTAGTT
GGAGCTT 
/5Cy5/CACTC
TTGCCTACG
CCACA 
/56-FAM/AAT ATA 
AAC TTG TGG 
TAG TTG GAG 
CTT 
/5LTC640N/GCA 
CTC TTG CCT ACG 
CCA CA 
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FRETplexing 
 
There are three significant problems with quechiplexing that are corrected by 
utilizing the FRETplexing assay. The first problem is generating a negative assay. Most 
experiments generate a positive response, so generating a negative response might be 
problematic to some. The second significant problem with quechiplexing is measuring a 
decrease in signal, assuming that it is the result of quenching, but that might not be the 
case; there are several things that absorb light, both biological and material, that can 
result in false quenching.  The third problem is sensitivity. Many tools are used to detect 
trace amount of light, down to a single photon, yet it is significantly more difficult to 
detect the difference between a large starting number of photons and a sight reduction of 
photons. To help remedy these problems FRETplexing was developed. With 
FRETplexing you generate a positive response that is nearly identical to an iconic PCR 
response and with FRETplexing you eliminate the false positive generated for 
unexpected quenching. It is also unlikely that something in the system will cause the  
fluoraphore to activate with the optical filters in place to block specific spectral ranges. 
With FRET detection dependent on measuring fluorescence the systems in place are 
already designed for this kind of detection, increasing the sensitivity compared to 
quenchiplexing. 
 The primers used for the FRET system are displayed in Table 6.13; the multiple 
generations of primers were optimizing the primers for the commercial system. To ensure 
that FRETplexing works the same as quechiplexing the experiments were duplicated 
(table 6.14-6.15). The same PCR and replicates was used as the experiment before, the 
only change is the reverse primer having a fluoraphore. The resulting data was used to 
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generate Figures 6.19-6.20. As expected an iconic PCR graph was generated, which is the 
desired result. When examining the deltas of each graph we get values of 0.3A.U for 1x 
concentration. This proves that like quenchiplexing, FRETplexing assay works and it is 
possible to use intensity coding with quenchiplexing for multiplexing assays. Since the 
was validated and confirmed, it was time to test the combination of mutation 
concentrations to generate the 3x, 5x, 6x, and 7x concentrations that should result by 
adding the different primer combinations together. 
 
Components	  	   Volume	  (uL)/Concentration(uM)	  Reagents	  	   20uL	  of	  100	  uM	  Taq	  5x	  matermix	  WT	   10uL	  of	  100uM	  216T	  	   10uL	  of	  10uM	  	  
216T	  primer	  1×	   2	  uL	  of	  10uM	  forward	  and	  reverse	  primer	  
Table 6.14. Experiment Cocktail for Detection of a Single 216T Mutation Using 
FRETplexing. 
Components	  	   Volume	  (uL)/Concentration(uM)	  Reagents	  	   20uL	  of	  100	  uM	  Taq	  5x	  matermix	  WT	   10uL	  of	  100uM	  216C	  	   10uL	  of	  10uM	  	  
216C	  primer	  2×	   4	  uL	  of	  10uM	  forward	  and	  reverse	  primer	  
Table 6.15. Experiment Cocktail for Detection of a Single 216C Mutation Using 
FRETplexing. 
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Figure 6.19.FRETplexing Assay for 216T 1x Concentration. Chart reporting detection of 216T mutant 
sequence from KRAS gene using FRET-chromophore-labeled primers with quantitative PCR (qPCR). The 
assay contains 2uL of 10uM forward and reverse primer concentration, 20uL of Taq 5x mastermix, 10uL of 
10uM 216T mutant sequence, and 10uL of 100uM wild type sequence. The forward primer is labeled with 
Cy3 as a FRET donor chromophore and the reverse primer is labeled with Cy5 as a FRET acceptor 
chromophore. The chart shows an averaged FRET emission signal intensity of 10 qPCR experiments (y-
axis) plotted as a function of PCR cycles (x-axis) with a standard deviation of 1σ. The FRET emission 
signal intensity is generated by Cy5 (y-axis) and detected after each annealing step. The delta value 
calculated by subtracting the maximum FRET signal recorded during the PCR saturation period and the 
minimum FRET signal recorded at the beginning of the PCR cycles is 0.27 A.U. The PCR reaction system 
reaches saturation at cycle 19 and the exponential growth begins at cycle 8.    
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Figure 6.20. FRETplexing Assay for 216T 2x Concentration. Chart reporting detection of 216C mutant 
sequence from KRAS gene using FRET-chromophore-labeled primers with quantitative PCR (qPCR). The 
assay contains 4uL of 10uM forward and reverse primer concentration, 20uL of Taq 5x mastermix, 10uL of 
10uM 216C mutant sequence and 10uL of 100uM wild type sequence. The forward primer is labeled with 
Cy3 as a FRET donor chromophore and the reverse primer is labeled with Cy5 as a FRET acceptor 
chromophore. The chart shows an averaged FRET emission signal intensity of 10 qPCR replica 
experiments (y-axis) plotted as a function of PCR cycles (x-axis) with a standard deviation of 1σ. The 
FRET emission signal intensity is generated by Cy5 (y-axis) and detected after each annealing step. 
 
 Repeating the experiment from the quenchiplexing assay reagents I combined 
multiple mutations in a single reaction to observe the multiplexing behavior of the assay. 
The experimental protocols are displayed in Tables 6.16-6.19 and the resulting data is 
graphed in Figures 6.21-6.24.  Using the data from the graphs 6.21-6.24 and using the 
single mutation experiments (Figure 6.19 and 6.20) deltas were determined and graphed 
in Figure 6.25. Using the generated delta, a graph can visualize the ability of the 
FRETplex assay to multiplex K-RAS mutations. The delta graph should in theory be 
linear and Figure 6.25 does tend to be linear, but once the concentration reaches the 6x 
level the system start to loose linearity. This is not surprising since, as expressed before, 
the sequence and primers have a high degree of similarity, creating a statistical problem.  
 
Table 6.16. Experiment Cocktail for Detection of a Double Mutation 216C at 2× and 216T at 1× Primer 
Concentrations Using FRETplexing. 
Components	  	   Concentration	   Volume	  
Reagents	  	   100uM	   20uL	  WT	   100uM	   10uL	  216C	   10uM	   10uL	  
216T	   10uM	   10uL	  
216C	  Primer	   10uM	   4uL	  
216T	  Primer	   10uM	   2uL	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Table 6.17. Experiment Cocktail for Detection of a Double Mutation 216C at 2× and 216A at 4× Primer 
Concentrations Using FRETplexing. 
Table 6.18. Experiment Cocktail for Detection of a Double Mutation 216T at 1× and 216A at 4× Primer 
Concentrations Using FRETplexing. 
Components	  	   Concentration	   Volume	  
Reagents	  	   100uM	   20uL	  WT	   100uM	   10uL	  216C	   10uM	   10uL	  
216A	   10uM	   10uL	  
216C	  Primer	   10uM	   4uL	  
216A	  Primer	   10uM	   8uL	  
Components	  	   Concentration	   Volume	  
Reagents	  	   100uM	   40uL	  WT	   100uM	   10uL	  216T	   10uM	   10uL	  
216A	   10uM	   10uL	  
216T	  Primer	   10uM	   2uL	  
216A	  Primer	   10uM	   8uL	  
Components	  	   Concentration	   Volume	  
Reagents	  	   100uM	   40uL	  WT	   100uM	   10uL	  216C	   10uM	   10uL	  
216T	   10uM	   10uL	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Table 6.19. Experiment Cocktail for Detection of a Triple Mutation 216C at 2× and 216T at 1× and 216A 
at 4× Primer Concentrations Using FRETplexing. 
 
 
Figure 6.21. FRETplexing Assay for 216T at1x and 216A at 4x Concentration. Chart reporting detection of 
double mutation 216T and 216A from KRAS gene using FRET-chromophore-labeled primers with 
quantitative PCR (qPCR). The assay contains 8uL of 10uM forward and reverse primer concentration for 
216A, 2uL of 10uM forward and reverse primer concentration for 216T, 20uL of Taq 5x mastermix, 10uL 
of 10uM for each 216A and 216T mutant, and 10uL of 100uM wild type sequence. The forward primer is 
labeled with Cy3 as a FRET donor chromophore and the reverse primer is labeled with Cy5 as a FRET 
acceptor chromophore. The chart shows an averaged FRET emission signal intensity of 10 qPCR replica 
experiments (y-axis) plotted as a function of PCR cycles (x-axis) with a standard deviation of 1σ. The 
FRET emission signal intensity is generated by Cy5 (y-axis) and detected after each annealing step. 
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Figure 6.22. FRETplexing Assay for 216T at1x and 216C at 2x Concentration. Chart reporting detection of 
double mutation 216T and 216C from KRAS gene using FRET-chromophore-labeled primers with 
quantitative PCR (qPCR). The assay contains 4uL of 10uM forward and reverse primer concentration for 
216C, 2uL of 10uM forward and reverse primer concentration for 216T, 20uL of Taq 5x mastermix, 10uL 
of 10uM for each 216C and 216T mutant, and 10uL of 100uM wild type sequence. The forward primer is 
labeled with Cy3 as a FRET donor chromophore and the reverse primer is labeled with Cy5 as a FRET 
acceptor chromophore. The chart shows an averaged FRET emission signal intensity of 10 qPCR replica 
experiments (y-axis) plotted as a function of PCR cycles (x-axis) with a standard deviation of 1σ. The 
FRET emission signal intensity is generated by Cy5 (y-axis) and detected after each annealing step. 
 
Figure6.23.FRETplexing Assay for 216A at4x and 216C at 2x Concentration. Chart reporting detection of 
double mutation 216A and 216C from KRAS gene using FRET-chromophore-labeled primers with 
quantitative PCR (qPCR). The assay contains 4uL of 10uM forward and reverse primer concentration for 
216C, 8uL of 10uM forward and reverse primer concentration for 216A, 20uL of Taq 5x mastermix, 10uL 
of 10uM for each 216A and 216C mutant, and 10uL of 100uM wild type sequence. The forward primer is 
labeled with Cy3 as a FRET donor chromophore and the reverse primer is labeled with Cy5 as a FRET 
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acceptor chromophore. The chart shows an averaged FRET emission signal intensity of 10 qPCR replica 
experiments (y-axis) plotted as a function of PCR cycles (x-axis) with a standard deviation of 1σ. The 
FRET emission signal intensity is generated by Cy5 (y-axis) and detected after each annealing step. 
 
Figure 6.24 FRETplexing Assay for 216T at 1x, 216A at4x and 216C at 2x Concentration. Chart reporting 
detection of triple mutation 216A, 216T and 216C from KRAS gene using FRET-chromophore-labeled 
primers with quantitative PCR (qPCR). The assay contains 4uL of 10uM forward and reverse primer 
concentration for 216C, 8uL of 10uM forward and reverse primer concentration for 216A, 2uL of 10uM 
forward and reverse primer concentration for 216T, 20uL of Taq 5x mastermix, 10uL of 10uM for each 
216A, 216T and 216C mutant, and 10uL of 100uM wild type sequence. The forward primer is labeled with 
Cy3 as a FRET donor chromophore and the reverse primer is labeled with Cy5 as a FRET acceptor 
chromophore. The chart shows an averaged FRET emission signal intensity of 10 qPCR replica 
experiments (y-axis) plotted as a function of PCR cycles (x-axis) with a standard deviation of 1σ. The 
FRET emission signal intensity is generated by Cy5 (y-axis) and detected after each annealing step. 
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Figure 6.25. FRETplex emission intensities (delta values) obtained from FIGs. 6.19-6.24. Plotted as a 
function of the accumulated primer concentration ratio (x-axis) with a standard deviation of 1σ. 
 
 Unfortunately, the data present in figure 6.25 reveals that multiplexing beyond 
two mutations in a single reaction is a problem for this specific K-RAS assay, but would 
more than likely not be a problem for sequence that does not have a high amount of 
sequence similarity, but what about the systems sensitivity? Does the FRETplex system 
have a high degree of sensitivity? Using 8uL each of 216A, T, and C forward and reverse 
primers (table 6.20), I spiked different concentration of wild type sequence to try and 
generate a false signal. The assay needs the mutation present in order to amplify the 
DNA, yet the system is not perfect, as mistakes happen and DNA will get amplified even 
if it is not the correct target. In Figure 6.26, the FRETplex system dose very well and 
limits the number of false positives generated, and only then does the wild type 
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concentration reach 100,000uM and the signal reaches half of the signal we observed in 
the 1x concentration displayed in Figure 6.19. This is a nice result for a cancer diagnostic 
assay, since mutation can be quite rare and if the system cannot distinguish between a 
low mutant concentrations to a high wild type concentrations it would be useless, yet 
having a assay with a high sensitivity can be beneficial in its own right. 
Components Concentration 
Reagents 20uL of Taq 5x mastermix 
Wild Type Sequence 10uL of 10uM, 100uM, 1000uM 10,000uM 
or 100,000uM 
216T Primers 8uL of 10uM 
216A Primers 8uL of 10uM 
216C Primers 8uL of 10uM 
Table 20. FRETplexing Experiment Cocktail for Control Experiments Using Wild Type Sequences. 
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Figure 6.26.Wild Type Concentration Calibration Experiments Using FRET-Chromophore-Labeled 
Primers with qPCR. Each multiplexed assay contains 20uL of Taq 5x matermix, 8 uL of 10uM for each 
primer 216C, 216A, and 216T, and the WT sequence at different volumes (10uL, 100uL, 1000uL, 
10,000uL, and 100,000uL). The y-axis shows averaged relative FRET emission intensities obtained from 
22 qPCR replica experiments. For each qPCR experiment, the relative FRET emission intensity (delta 
value) is calculated by subtracting the maximum FRET emission intensity with the minimum FRET 
emission intensity. 
 
 Using the same experiment design form Table 6.20, I added 2uL of 216C, 216T, 
or 216A individually, and this will generate a simple test to determine if a mutation is 
present or not. The resulting experimental data is graphed in Figure 6.27. From the graph 
we can observe that the mutation fluorescent signal is higher that just the wild type alone. 
This information can be used to develop a simple yes/no assay to determine if any K-
RAS mutation is present. This information would be very useful during a surgery where 
the surgeon only cares if a tissue is carcinogenic and not what specific mutations are 
causing the cancer. 
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Figure 6.27. KRAS Yes No Diagnostic Assay. Chart reporting the detection of the presence or absence of a 
KRAS mutation 216A, 216T, and 216C using FRETplexing with qPCR. Each multiplexed assay contains 
20uL of Taq 5x matermix, 10uL of 10uM for a given mutant sequence, and 8uL of 10uM primer 
concentration for each of three primer pairs. The forward primer is labeled with Cy3 as a FRET donor 
chromophore and the reverse primer is labeled with Cy5 as a FRET acceptor chromophore. The chart 
shows averaged relative FRET emission intensities (delta values at y-axis) of 12 qPCR replica experiments 
plotted for each mutation also in comparison with wild type assay at two different concentrations: 10uL of 
100uM wild type in one experiment and 10uL of 1000uM wild type in the other experiment. 
 
Conclusion 
 Personalized medicine is the future of the medical industry, but this will come at a 
significant increase in diagnostic cost. The specific knowledge of an individual’s genetic 
makeup can determine if a specific drug will be beneficial in that person’s treatment. In 
the specific case of cancer, it was shown that colorectal cancer patients will have 
different success rates on different drugs, depending on what specific mutations they 
have in the KRAS gene.98-100Yet unless you have familial genetic history for a specific 
cancer, and will have a unique set of mutations that caused that cancer to develop. There 
is a need to obtain genetic data for every person undergoing treatment, and unfortunately 
this will apply increased pressure on already limited resources and increase the initial 
cost of treatment, so there is a great need for cheaper and faster diagnostics.  
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Quenchiplexing and FRETplexing are both potential solutioa to this problem of 
faster and cheaper diagnostics. Both technologies are advantageous, and since both 
generate genetic data during PCR amplification of the material, a step normally needed 
when doing genetic analysis; they also have the potential of eliminating the sequencing or 
gel step needed for mutation identification. This will have a two-fold impact. The first is 
reducing the cost of diagnostics, since only a few tests and reagents need to be used with 
decreases in the amount of labor required for performing the diagnostic test.  The second 
impact occurs by decreasing the time between obtaining the sample and generating an 
answer. With the technology described in this thesis, PCR can now be accomplished in a 
matter of minutes, significantly reducing diagnostic time. 
 In an age of rising medical costs, innovations are needed to combat these 
increases.  Quenchiplexing and FRETplexing can accomplish this by increasing the 
diagnostic capabilities of instruments we already use and provide more information than 
what would be traditionally obtained. Although they are limited in ability, the small 
improvement in time and cost can have a significant impact. Using a surgical example, it 
is possible to do diagnostic tests on tissue during surgery with these to methods.  This 
could allow the surgeon to more accurately remove cancerous tissue, potentially 
preventing another surgery, which would be a significant improvement in care.  
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Chapter 7 
Summation 
 
There is a significant need to generate new diagnostic medical devices to advance and 
improve our understanding of biological concepts, but to devise new methods and 
techniques to advance medical diagnostics into the realm of gene therapy and 
personalized medicine.  There is a problem with growing medical costs coupled with cost 
effective therapy that requires medical facilities increase the efficiency and effectiveness 
of therapeutic modalities.  Microfluidics was developed to help develop expensive 
laboratory equipment towards cheap low cost devices that could be implemented at the 
point of care. This thesis displays the potential to incorporate the technologies of diverse 
educational disciplines (chemistry, physics, engineering, and material science) in order to 
solve complex biological problems and applications. 
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